bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

1

Comprehensive evolution and molecular characteristics of a large number of

2

SARS-CoV-2 genomes revealed its epidemic trend and possible origins

3
4

Yunmeng Bai1#, Dawei Jiang1#, Jerome R Lon1#, Xiaoshi Chen1, Meiling Hu1, Shudai Lin1, Zixi Chen1,

5

Xiaoning Wang1,2, Yuhuan Meng3*, Hongli Du1*

6

1

7

510006, China

8

2

State Clinic Center of Gearitic, Chinese PLA General Hospital, Beijing 100853, China

9

3

Guangzhou KingMed Transformative Medicine Institute Co., Ltd, Guangzhou 510330, China

10

#

Equal contribution.

11

*

Corresponding authors.

12

E-mail: hldu@scut.edu.cn, zb-mengyuhuan@kingmed.com.cn

School of Biology and Biological Engineering, South China University of Technology, Guangzhou

13
14

Abstract

15

Objectives:

16

To reveal epidemic trend and possible origins of SARS-CoV-2 by exploring its evolution and

17

molecular characteristics based on a large number of genomes since it has infected millions of

18

people and spread quickly all over the world.

19

Methods:

20

Various evolution analysis methods were employed.

21

Results:
1

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

22

The estimated Ka/Ks ratio of SARS-CoV-2 is 1.008 or 1.094 based on 622 or 3624 SARS-CoV-2

23

genomes, and the time to the most recent common ancestor (tMRCA) was inferred in late

24

September 2019. Further 9 key specific sites of highly linkage and four major haplotypes H1, H2,

25

H3 and H4 were found. The Ka/Ks, detected population size and development trends of each

26

major haplotype showed H3 and H4 subgroups were going through a purify evolution and almost

27

disappeared after detection, indicating H3 and H4 might have existed for a long time, while H1

28

and H2 subgroups were going through a near neutral or neutral evolution and globally increased

29

with time. Notably the frequency of H1 was generally high in Europe and correlated to death rate

30

(r>0.37).

31

Conclusions:

32

In this study, the evolution and molecular characteristics of more than 16000 genomic sequences

33

provided a new perspective for revealing epidemiology of SARS-CoV-2.

34
35

KEYWORDS: SARS-CoV-2; evolution; classification; haplotype

36
37

Introduction

38

The global outbreak of SARS-CoV-2 is currently and increasingly recognized as a serious, public

39

health concern worldwide. Coronaviruses exist widely around the world, and to date, a total of seven

40

types of coronaviruses that can infect humans have been found, of which four coronaviruses including

41

hCoV-229E, hCoV-NL63, hCoV-OC43 and hCoV-HKU1 cause a cold, while the other three including

42

SARS-CoV, MERS-CoV and SARS-CoV-2 usually cause mild to severe respiratory diseases. The total
2

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

43

number of SARS-CoV and MERS-CoV infections are only 8,069 and 2,494 with reproduction number

44

(R0) fluctuates 2.5-3.9 and 0.3-0.8, respectively. However, SARS-CoV-2 has infected 2471136 people

45

in 212 countries up to April 22th(WHO, 2020), with the basic R0 ranging from 1.4 to 6.49(Liu, et al.,

46

2020). Among these three typical coronavirus, MERS-CoV has the highest death rate of 34.40%,

47

SARS-CoV has the modest death rate of 9.59%, SARS-CoV-2 is about 6.99% and 7.69% death rate of

48

the global and Wuhan, but is quite high death rate in some countries of Europe, such as Belgium, Italy,

49

United Kingdom, Netherlands, Spain and France, which even reaches 14.95%, 13.39%, 13.48%,

50

11.61%, 10.42% and 13.60% respectively according to the data of April 22th, 2020. Except for the

51

shortage of medical supplies, aging and other factors, it is not clear whether there is virus mutation

52

effect in these countries with such a significantly increased death rate.

53

It has been reported that SARS-CoV-2 belongs to beta-coronavirus and is mainly transmitted by the

54

respiratory tract, which belongs to the same subgenus (SarbeCoVirus) as SARS-CoV(Lu, et al., 2020).

55

Through analyzing the genome and structure of SARS-CoV-2, its receptor-binding domain (RBD) was

56

found to bind with angiotensin-converting enzyme 2 (ACE2), which is also one of the receptors for

57

binding SARS-CoV(Wrapp, et al., 2020). Some early genomic studies have shown that SARS-CoV-2 is

58

similar to certain bat viruses (RaTG13, with the whole genome homology of 96.2%(Zhou, et al., 2020))

59

and Malayan pangolins coronaviruses (GD/P1L and GDP2S, with the whole genome homology of

60

92.4%(Lam, et al., 2020)). They have speculated several possible origins of SARS-CoV-2 based on its

61

spike protein characteristics (cleavage sites or the RBD)(Lam, et al., 2020, Zhang and Holmes, 2020,

62

Zhou, et al., 2020), in particular, SARS-CoV-2 exhibits 97.4% amino acid similarity to the Guangdong

63

pangolin coronaviruses in RBD, even though it is most closely related to bat coronavirus RaTG13 at
3

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

64

the whole genome level. However, it is not enough to present genome-wide evolution by a single gene

65

or local evolution of RBD, whether bats or pangolins play an important role in the zoonotic origin of

66

SARS-CoV-2 remains uncertain(Andersen, et al., 2020). Furthermore, since there is little molecular

67

characteristics analysis of SARS-CoV-2 based on a large number of genomes, it is difficult to

68

determine whether the virus has significant variation that affects its phenotype. Thereby, it is necessary

69

to further reveal the phylogenetic evolution and molecular characteristics of the whole genome of

70

SARS-CoV-2 in order to develop a comprehensive understanding of the virus and provide a basis for

71

the prevention and treatment of SARS-CoV-2.

72
73

Results

74

Genome sequences

75

We got a total of 1053 genomic sequences up to March 22th, 2020. According to the filter criteria, 37

76

sequences with ambiguous time, 314 with low quality and 78 with similarity of 100% were removed. A

77

total of 624 sequences were obtained to perform multiple sequences alignment. Two highly divergent

78

sequences (EPI_ ISL_414690, EPI_ISL_415710) according to the firstly constructed phylogenetic tree

79

were also filtered out (Table S1). The remaining 622 sequences were used to reconstruct a phylogenetic

80

tree. In addition, total of 3624 and 16373 genomic sequences were redownloaded up to April 6th, 2020

81

and May 10th, 2020 respectively for further exploring the evolution and molecular characteristics of

82

SARS-CoV-2.

4

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

83

Estimate of evolution rate and the time to the most recent common ancestor for SARS-CoV,

84

MERS-CoV, and SARS-CoV-2

85

In this study, date for SARS-CoV-2 ranged from 2019/12/26 to 2020/03/18 was collected. The average

86

Ka/Ks of all the coding sequences was closer to 1 (1.008), which indicating the genome was going

87

through a neutral evolution. We also reevaluated the Ka/Ks of SARS-CoV and MERS-CoV through the

88

whole period, and found the ratio were smaller than SARS-CoV-2 (Table 1). To estimate more credible

89

Ka/Ks for SARS-CoV-2, we recalculated it using redownloaded 3624 genome sequences ranged from

90

2019/12/26 to 2020/04/06, and the average Ka/Ks of it was 1.094 (Table 1), which was almost same

91

with the above result.

92

We assessed the temporal signal using TempEst v1.5.3(Rambaut, et al., 2016). All three datasets

93

exhibit a positive correlation between root-to-tip divergence and sample collecting time (Figure S1),

94

hence they are suitable for molecular clock analysis in BEAST(Bouckaert, et al., 2019, Rambaut, et al.,

95

2016). The substitution rate of SARS-CoV-2 genome was estimated to be 1.601 x 10-3 (95% CI: 1.418 x

96

10 -3 - 1.796 x 10-3, Table 2, Figure S2A) substitution/site/year, which is as in the same order of

97

magnitude as SARS-CoV and MERS-CoV. The tMRCA was inferred on the late September, 2019 (95%

98

CI: 2019/08/28- 2019/10/26,Table 2, Figure S2B), about 2 months before the early cases of

99

SARS-CoV-2(Huang, et al., 2020).

100

Phylogenetic tree and clusters of SARS-CoV-2

101

The no-root phylogenetic trees constructed by the maximum likelihood method with PhyML

102

3.1(Guindon, et al., 2010) and MEGA(Kumar, et al., 2018) were showed in Figure 1, Figure S3A and

103

3B. According to the shape of phylogenetic trees, we divided 622 sequences into three clusters: Cluster
5

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

104

1 including 76 sequences mainly from North America, Cluster 2 including 367 sequences from all

105

regions of the world, and Cluster 3 including 179 sequences mainly from Europe (Table S2).

106

The specific sites of each Cluster

107

The Fst and population frequency of a total of 9 sites (NC_045512.2 as reference genome) were

108

detected (Table 3, Table S3). Thereinto, three (C17747T, A17858G and C18060T) are the specific sites

109

of Cluster 1, and four (C241T, C3037T, C14408T and A23403G) are the specific sites of Cluster 3.

110

Notably, C241T was located in the 5’-UTR region and the others were located in coding regions (6 in

111

ofr1ab gene, 1 in S gene and 1 in ORF8 gene). Five of them were missense variant, including C14408T,

112

C17747T and A17858G in ofr1ab gene, A23403G in S gene, and T28144C in ORF8 gene. The PCA

113

results showed that these 9 specific sites could clearly separate the three Clusters, while all SNV

114

dataset could not clearly separate Cluster 1 and Cluster 2 (Figure S4), which further suggested that

115

these 9 specific sites are the key sites for separating the three Clusters.

116

Linkage of specific sites

117

We found the 9 specific sites are highly linkage based on 622 genome sequences (Figure 2A), then we

118

carried out a further linkage analysis using the 3624 genome sequences (Figure 2B). As a result, for the

119

3624 genome sequences, 3 specific sites in the Cluster 1 were almost complete linkage, and haplotype

120

CAC and TGT accounted for 98.65% of all the 3 site haplotypes. The same phenomenon was also

121

found in 4 specific sites of Cluster 3, and haplotype CCCA and TTTG accounted for 97.68% of all the

122

4 site haplotypes. Intriguingly, the 9 specific sites were still highly linkage, and four haplotypes,

123

including TTCTCACGT (H1), CCCCCACAT (H2), CCTCTGTAC (H3) and CCTCCACAC (H4),

124

accounted for 95.89% of all the 9 site haplotypes. Thereinto, H1 and H3 had completely different bases
6

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

125

at the 9 specific sites. The frequencies of each site and major haplotype for each country were showed

126

in Figure 3 and Table S4. The data showed that the haplotype TTTG of the 4 specific sites in Cluster 3

127

had existed globally at present, and still exhibited high frequencies in most European countries but

128

quite low in Asian countries. While the haplotype TGT of the 3 specific sites in Cluster 1 existed

129

almost only in North America and Australia. For the 9 specific sites, most countries had only two or

130

three major haplotypes, except America and Australia had all of four major haplotypes and with

131

relative higher frequencies.

132

Characteristics and epidemic trends of major haplotype subgroups

133

All haplotypes of 9 specific sites for 3624 or 16373 genomes and the numbers of them were shown in

134

Table S5. Four major haplotypes H1, H2, H3 and H4, three minor haplotypes H5, H7 and H8 close to

135

H1 and one minor haplotype H6 close to H3 were found in both datasets. The numbers of these

136

haplotypes for 16373 genomes with clear collection data detected in each country in chronological

137

order were shown in Figure 4A. From these results, H2 and H4 haplotype subgroups had existed for a

138

long time (2019-12-24 to 2020-04-28), the detected population size of H2 subgroup was far greater

139

than that of H4 subgroup, and the H3 haplotype subgroup almost disappeared after detection

140

(2020-02-18 to 2020-04-28), while H1 haplotype subgroup was globally increasing with time

141

(2020-02-18 to 2020-05-05), which indicated H1 subgroup had adapted to the human hosts, and was

142

under an adaptive growth period worldwide. However, due to the nonrandom sampling on early phase

143

(only patients having a recent travel to Wuhan were detected), some earlier cases of H3 may be lost, the

144

high proportion of H3 subgroup during February 18 to March 10 could confirm this point.

145

H3 and H4 subgroups had the lowest Ka/Ks ratio in 3624 or 16373 genomes among the 4 major
7

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

146

subgroups (Table 4), suggesting that H3 and H4 subgroups might be going through a purifying

147

evolution and have existed for a long time, while H2 and H1 subgroups might be going through a near

148

neutral or neutral evolution according to their Ka/Ks ratios (Table 4), which were consistent with the

149

above phenomenon that only H1 and H2 subgroups were expanding with time around the world. From

150

the whole genome mutations in each major haplotype subgroup (Figure 4B, Table S6), we found that

151

except the 9 specific sites, there was no common mutations with frequencies more than 0.05 in these

152

haplotype subgroups but between H2 and H4 subgroups.

153

Phylogenetic network of haplotype subgroups

154

Phylogenetic networks were inferred with 697 mutations called from 3624 genomes dataset. For these

155

datasets, the network structures of TCS and MSN were similar. The major haplotype subgroups H4 and

156

H2 were in the middle of the network, while H1 and H3 were in the end nodes of the network (Figure

157

5). According to the phylogenetic networks, we proposed four hypothesis: (1) the ancestral haplotypes

158

evolved in four directions to obtain H1, H2, H3 and H4 respectively or evolved in two or more

159

directions to obtain two or more major haplotypes and then involved into the other major haplotype(s);

160

(2) H2 or H4 evolved in two directions respectively and finally generated H1 and H3; (3) H1 evolved

161

in one direction to generate H2 and H4, and then evolved into H3; (4) H3 evolved in one direction to

162

generate H4 and H2, and then evolved into H1. Although we cannot exclude the first hypothesis based

163

on the present data, but if there are evolutionary relationships among the four major haplotypes,

164

according to the Ka/Ks, detected population size and development trends in chronological order of each

165

major haplotype subgroup, we speculate that the most likely evolution hypothesis is that H3 and H4 are

166

the earliest haplotypes, which is gradually eliminated with selection, while H2 is the transitional
8

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

167

haplotype in the evolution process, and H1 may be the haplotype to be finally fixed.

168

Correlation analysis of specific sites with death rate and infectivity

169

To explore the relationship between death rate and the 9 specific sites, we used Pearson method to

170

calculate the correlation coefficient between death rate and frequency of each specific site or major

171

haplotype in 17 countries with 3624 genomes at early stage. As a result, all r values of 241T, 3037T,

172

14408T, 23403G and haplotype TTTG and H1 were more than 0.4 (Figure 6, Table S4). We also

173

evaluated the correlation coefficient with 16373 genomes in 30 countries, the r values of haplotype

174

TTTG and H1 were still more than 0.37 (Table S4), which might be increased when the death rates of

175

some countries were further stabilized with time. These finding integrating their high frequencies in

176

most European countries indicated that the 4 sites and haplotype TTTG and H1 might be related to the

177

pathogenicity of SARS-CoV-2.

178

To explore the relationship between infectivity and the 9 specific sites, we used population size of

179

major haplotypes to deduce the possible specific sites related infectivity. We assumed that these major

180

haplotype in each country were subject to similar virus transmission and control patterns, while the

181

population sizes of H1 and H2 subgroups were far greater than those of H3 and H4 subgroups (Figure

182

4A, Table S4), then the common different specific sites of H1 and H2 subgroups with H3 and H4

183

subgroups, C8782T and T28144C, might be related to the infectivity of SARS-CoV-2, and the virus

184

with C8782 and T28144 might be more infectious than those virus with 8782T and 28144C.

185
186

Discussion

187

SARS-CoV-2 poses a great threat to the production, living and even survival of human beings(Guo, et
9

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

188

al., 2020). With the further outbreak of SARS-CoV-2 in the world, further understanding on the

189

evolution and molecular characteristics of SARS-CoV-2 based on a large number of genome sequences

190

will help us cope better with the challenges brought by SARS-CoV-2.

191

Exploring evolution rate, tMRCA and phylogenetic tree of SARS-CoV-2 would help us better

192

understand the virus(Yuen, et al., 2020). The average Ka/Ks for all the coding sequences of 622 and

193

3624 SARS-CoV-2 genomes was 1.008 and 1.094, which was higher than those of SARS-CoV and

194

MERS-CoV, indicating that the SARS-CoV-2 was going through a neutral evolution. In general,

195

SARS-CoV would show purifying selection pressures and the Ka/Ks would go down at the middle or

196

end of the epidemic(He, et al., 2004). Therefore, it seemed to be reasonable considering that

197

SARS-CoV-2 was under an exponential growth period around the world. Interestingly, we also found

198

that the subgroups of different haplotypes (H1, H2, H3 and H4) seemed to experience different

199

evolutionary patterns according to their Ka/Ks. The H3 haplotype subgroup disappeared soon after

200

detection (2020-02-18 to 2020-04-28, Figure 4A), while H1 haplotype subgroup was globally

201

increasing with time, these evolution and changes should be considered in developing therapeutic drugs

202

and vaccines. The tMRCA of SARS-CoV-2 was inferred on the late September, 2019 (95% CI:

203

2019/08/28- 2019/10/26), about 2 months before the early cases of SARS-CoV-2(Huang, et al., 2020).

204

We also estimated tMRCA of SARS-CoV and MERS-CoV with the same methods, both were about 3

205

months later than the corresponding tMRCAs estimated by previous studied(Cotten, et al., 2014, Zhao,

206

et al., 2004). A recent study used TreeDater method to estimate tMRCA for more than 7000

207

SARS-CoV-2 genomes and indicated the tMRCA of SARS-CoV-2 was around 6 October 2019 to 11

208

December 2019, which were about one and a half months later than ours and in broad agreement with
10

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

209

six previous studies all performed on no more than 120 early SARS-CoV-2 genomes with BEAST

210

method(van Dorp, et al., 2020). While we used the most common method BEAST to estimate tMRCA

211

of SARS-CoV-2 based on 622 genomes and combined with the comparison of tMRCA of SARS-CoV

212

and MERS-CoV, indicating that the estimated tMRCA in the present study are more reliable.

213

A recent study clustered 160 SARS-CoV-2 whole-genome sequences into A, B and C groups by a

214

phylogenetic network analysis by taking bat RaTG13 as root (Forster, et al., 2020). The cluster result

215

was similar to our study: both the samples in Cluster A and our Cluster 1 were mainly from the United

216

States; the samples in Cluster C and our Cluster 3 were mainly from European countries, while Cluster

217

B and our Cluster 2 were mainly from China and the other regions. It was interesting that the markers

218

C8782T and T28144C, which were also discovered by Yu et al(Yu, et al., 2020) , in Cluster B were

219

also found in our study, but the other markers in Cluster A (T29095C) and Cluster C (G26144T) were

220

not significantly in our study. That may be caused by different sample sizes and different constructing

221

methods of phylogenetic tree. Based on the base substitution model, the ML method avoids the

222

possible "long-branch attraction" problem in the maximum parsimony method and is faster than the

223

Bayesian method(Holder and Lewis, 2003), hence it could be used as a reliable method for

224

phylogenetic analysis. Some studies used the genome of bat SARS-like-CoV(Zhang, et al., 2020),

225

RaTG13(Zhang, et al., 2020) or MT019529 (https://bigd.big.ac.cn/ncov/tree) as the root of

226

phylogenetic tree. Unfortunately, there was no obvious evidence showing that SARS-CoV-2 was from

227

the bat coronavirus even the identity between SARS-CoV-2 and RaTG13 was up to 96.2%(Zhou, et al.,

228

2020). In our study, the tMRCA of SARS-CoV-2 was inferred on the late September 2019, which

229

indicated there might exist an earlier SARS-CoV-2 strain we didn't find. Then in the case of unclear
11

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

230

source of SARS-CoV-2 and high homology of its genomes (> 99.9% homology mostly), it may be

231

inappropriate to identify the evolutionary characteristics inside the genomes by taking bat

232

SARS-like-CoV, RaTG13 or MT019529 as root. Therefore, the maximum likelihood method was used

233

in current study to construct a no-root tree to obtain the reliable clusters with different characteristics.

234

Based on the no-root tree, we identified 9 specific sites of highly linkage that play a decisive role in the

235

classification of clusters successfully. Among the four major haplotypes, H1 and H3 were in Cluster 3

236

and Cluster 1, respectively, while there were two haplotypes H2 and H4 in Cluster 2 (Figure 1, Figure

237

S3B).

238

Among the 9 specific sites, 8 of them were located in coding regions (6 in ofr1ab gene, 1 in S gene

239

and 1 in ORF8 gene), and 5 of them were missense variant, including C14408T, C17747T and

240

A17858G in ofr1ab gene, A23403G in S gene, and C28144T in ORF8 gene. Orf1ab is composed of

241

two partially overlapping open reading frames (orf), orf1a and 1b. It is proteolytic cleaved into 16

242

non-structural proteins (nsp), including nsp1 (suppress antiviral host response), nsp9 (RNA/DNA

243

binding activity), nsp12 (RNA-dependent RNA polymerase), nsp13 (helicase) and others(Chan, et al.,

244

2020), indicating the vital role of it in transcription, replication, innate immune response and

245

virulence(Graham, et al., 2008). C14408T with high frequencies of T in European countries were

246

located at nsp12 region, indicating that this missense variant might influence the role of RNA

247

polymerase. Spike glycoprotein, the largest structural protein on the surface of coronaviruses,

248

comprises of S1 and S2 subunits which mediating binding the receptor on the host cell surface and

249

fusing membranes, respectively(Li, 2016). It has been reported that S protein of SARS-CoV-2 can bind

250

angiotensin-converting enzyme 2 (ACE2) with higher affinity than that of SARS(Wrapp, et al., 2020,
12

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

251

Zhou, et al., 2020). Whether the missense variant of A23403G in S gene, which with high frequencies

252

of G in European countries, will change the affinity between S protein and ACE2 remains to be further

253

investigated.

254

It seems to take a long time to finally fix mutations according to the mutation frequency of each

255

subgroup. For example, H2 and H4 subgroups, which have been detected for more than four months

256

from December 24, 2019 to May 5, 2020 (Figure 4A), have more mutations with higher frequencies,

257

but the highest mutation frequency is only 0.486 at the position of 11083 (Figure 4B, Table S6). From

258

these phenomena, it can be inferred that it takes a long time for the specific sites of each major

259

subgroup to be fixed, but it may be faster if the early population is small. In addition, there is also the

260

possibility that an ancestor strain evolved in four directions by obtaining the specific mutations directly

261

and produced the four current major haplotypes, so the evolution time for obtaining four major

262

haplotypes may be shorter, which seems to be consistent with the phenomenon that four major

263

haplotypes can be detected in two months (Figure 4A). However, if there exist evolution relationship

264

among the major haplotypes of SARS-CoV-2, it is difficult to complete the evolution among the four

265

major haplotypes within two months (2019-12-24 to 2020-02-18, Figure 4A) at the current evolution

266

rate of each major haplotype population (Table 4). Therefore, we speculate that the transformation

267

among the four major haplotypes may have been completed for a long time, which have not been

268

detected. What's interesting is that only United States and Australia among 29 countries had all of four

269

major haplotypes and with relative higher frequency (Figure 4A, Table S4), which indicated that the

270

two countries are the most likely places where the virus appeared earlier based on all the present data.

271

Previous studies showed that the death rate of SARS-CoV-2 is affected by many factors, such as
13

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

272

medical supplies, aging, life style and other factors(Liu, et al., 2020, Malavolta, et al., 2020). However,

273

our study found that the 4 specific sites (C241T, C3037T, C14408T and A23403G) in the Cluster 3

274

were almost complete linkage, and the frequency of haplotype TTTG was generally high in European

275

countries and correlated to death rate (r>0.37) both based on 3624 or 16373 SARS-CoV-2 genomes,

276

which provides a new perspective to the reasons of relatively high death rate in Europe, and these

277

specific sites should be considered in designing new vaccine and drug development of SARS-CoV-2.

278

Two possible specific sites C8782T and T28144C related to the infectivity of SARS-CoV-2 were also

279

deduced in the present study, which would provide some basis for SARS-CoV-2 epidemiology.

280
281

Conclusion and prospective

282

The Ka/Ks ratio of SARS-CoV-2 and tMRCA of SARS-CoV-2 (95% CI: 2019/08/28- 2019/10/26)

283

indicated that SARS-CoV-2 might have completed the selection pressure of cross-host evolution in the

284

early stage and be going through a neutral evolution at present. The 9 specific sites with highly linkage

285

were found to play a decisive role in the classification of clusters. Thereinto, 3 of them are the specific

286

sites of Cluster 1 mainly from North America and Australia, 4 of them are the specific sites of Cluster 3

287

mainly from Europe in the early stage, both of these 3 and 4 specific sites are almost complete linkage.

288

The frequencies of haplotype TTTG for the 4 specific sites and H1 for 9 specific sites were generally

289

high in European countries and correlated to death rate (r>0.37) based on 3624 or 16373 SARS-CoV-2

290

genomes, which suggested these haplotypes might relate to pathogenicity of SARS-CoV-2 and

291

provided a new perspective to the reasons of relatively high death rates in Europe. The relationship

292

between the haplotype TTTG or H1 and the pathogenicity of SARS-CoV-2 needs to be further verified
14

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

293

by clinical samples or virus virulence test experiment, and the 9 specific sites with highly linkage may

294

provide a starting point for the traceability research of SARS-CoV-2. Given that the different evolution

295

patterns of different haplotypes subgroups, we should consider these evolution and changes in the

296

development of therapeutic drugs and vaccines.

297
298

Materials and methods

299

Genome sequences

300

The complete genome sequences of SARS-CoV-2 were downloaded from China National Center for

301

Bioinformation (https://bigd.big.ac.cn/ncov/release_genome/) and GISAID (https://www.gisaid.org/)

302

up to March 22th, 2020. The sequences were filtered out according to the following criteria: (1)

303

sequences with ambiguous time; (2) sequences with low quality which contained the counts of

304

unknown bases > 15 and degenerate bases > 50 (https://bigd.big.ac.cn/ncov/release_genome); (3)

305

sequences with similarity of 100% were removed to unique one. Finally, 624 high quality genomes

306

with precise collection time were selected and aligned using MAFFT v7 with automatic parameters.

307

Besides, the genome sequences of 7 SARS-CoV and 475 MERS-CoV were also downloaded from

308

NCBI (https://www.ncbi.nlm.nih.gov/), and the MERS-CoV dataset including samples collected from

309

both human and camel. In addition, for further exploring evolution and molecular characteristics of

310

SARS-CoV-2 based on the larger amount of genomic data, we redownloaded validation datasets of the

311

genome sequences from GISAID up to April 6th, 2020 and May 10th, 2020 respectively.

15

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

312

Estimate of evolution rate and the time to the most recent common ancestor for SARS-CoV,

313

MERS-CoV, and SARS-CoV-2

314

The average Ka, Ks and Ka/Ks for all coding sequences were calculated using KaKs_Calculator

315

v1.2(Zhang, et al., 2006), and the substitution rate and tMRCA were estimated using BEAST

316

v2.6.2(Bouckaert, et al., 2019). The temporal signal with root-to-tip divergence was visualized in

317

TempEst v1.5.3(Rambaut, et al., 2016) using a ML whole genome tree with bootstrap value as input.

318

For SARS-CoV and SARS-CoV-2, we selected a strict molecular clock and Coalescent Exponential

319

Population Model. For MERS-CoV, we selected a relaxed molecular clock and Birth Death Skyline

320

Serial Cond Root Model. We used the tip dates and chose the HKY as the site substitution model in all

321

these analyses. Markov Chain Monte Carlo (MCMC) chain length was set to 10,000,000 steps

322

sampling

323

(http://tree.bio.ed.ac.uk/software/tracer/).

324

Variants calling of SARS-CoV-2 genome sequences

325

Each genome sequence was aligned to the reference genome (NC_045512.2) using bowtie2 with

326

default parameters(Langmead and Salzberg, 2012), and variants were called by samtools (sort; mpileup

327

-gf) and bcftoots (call -vm). The merge VCF files were created by bgzip and bcftools (merge

328

--missing-to-ref)(Li, 2011, Li, et al., 2009).

329

Phylogenetic tree construction and virus isolates clustering for SARS-CoV-2

330

After alignment of 624 SARS-CoV-2 genomes with high quality and manually deleted 2 highly

331

divergent genomes (EPI_ISL_415710, EPI_ISL_414690) according to the firstly constructed

332

phylogenetic tree, the aligned dataset of 622 sequences was phylogenetically analyzed. The SMS

after

every

1000

steps.

The

16

output

was

examined

in

Tracer

v1.6

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

333

method was used to select GTR+G as the base substitution model(Lefort, et al., 2017), and the PhyML

334

3.1(Guindon, et al., 2010) and MEGA(Kumar, et al., 2018) were used to construct the no-root

335

phylogenetic tree by the maximum likelihood method with the bootstrap value of 100. The online tool

336

iTOL(Letunic and Bork, 2019) was used to visualized the phylogenetic tree. The clusters were defined

337

by the shape of phylogenetic tree.

338

Detection of specific sites from each Cluster

339

Information (ID, countries/regions and collection time) and variants (NC_045512.2 as reference

340

genome) of each genome from each Cluster were extracted. The allele frequency and nucleotide

341

divergency (pi) for each site in the virus population of each Cluster were measured by

342

vcftools(Danecek, et al., 2011). The Fst were also calculated by vcftools(Danecek, et al., 2011) to

343

assess the diversity between the Clusters. Sites with high level of Fst together with different major

344

allele in each Cluster were filtered as the specific sites. PCA were analyzed by the GCTA

345

v1.93.1beta(Yang, et al., 2011) with the specific sites and all SNV dataset respectively.

346

Linkage analysis of specific sites and characteristics of major haplotype subgroups

347

The linkage disequilibrium of the specific sites were analyzed by haploview(Barrett, et al., 2005), and

348

the statistics of the haplotype of the specific sites for each Cluster or country were used in-house perl

349

script.

350

Phylogenetic network of haplotype subgroups

351

The phylogenetic networks were inferred by PopART package v1.7.2(Leigh, et al., 2015) using TCS

352

and minimum spanning network (MSN) methods respectively.

17

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

353

Frequencies of specific sites or haplotypes and correlation with death rate

354

The frequencies of specific sites for each country were calculated. The death rate was estimated with

355

Total Deaths /Confirmed Cases based on the data from Johns Hopkins resources on May 12th, 2020

356

(https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6).The

357

correlation coefficient between death rate and frequencies of specific site or haplotype in different

358

countries was calculated using Pearson method.

359
360

Authors’ contributions

361

HD conceived the study. YM, YB, DJ, JL and XC carried out the data analysis and wrote the

362

manuscript. MH, SL, and ZC collected data and revised the manuscript. XW attended the discussions.

363

HD and YM supervised the whole work and revised the manuscript.

364

Conflict of Interest

365

The authors declare no conflict of interest.

366

Funding sources

367

This work was supported by the National Key R&D Program of China [2018YFC0910201], the Key

368

R&D Program of Guangdong Province [2019B020226001], the Science and the Technology Planning

369

Project of Guangzhou [201704020176 and 2020Q-P013].

370

Ethical Approval

371

Not required.

18

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

372
373

References

374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408

Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. (2020) The proximal origin of

409

Leigh JW, Bryant D, Nakagawa S. (2015) popart: full ‐ feature software for haplotype network

410

construction. Methods in Ecology and Evolution, 6:1110-6.

SARS-CoV-2. Nature Medicine, 10.1038/s41591-020-0820-9
Barrett JC, Fry B, Maller J, Daly MJ. (2005) Haploview: analysis and visualization of LD and
haplotype maps. Bioinformatics, 21:263-5.
Bouckaert R, Vaughan TG, Barido-Sottani J, et al. (2019) BEAST 2.5: An advanced software platform
for Bayesian evolutionary analysis. PLoS Comput Biol, 15:e1006650.
Chan JF, Kok KH, Zhu Z, et al. (2020) Genomic characterization of the 2019 novel human-pathogenic
coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes
Infect, 9:221-36.
Cotten M, Watson SJ, Zumla AI, et al. (2014) Spread, circulation, and evolution of the Middle East
respiratory syndrome coronavirus. mBio, 5:
Danecek P, Auton A, Abecasis G, et al. (2011) The variant call format and VCFtools. Bioinformatics
(Oxford, England), 27:2156-8.
Forster P, Forster L, Renfrew C, Forster M. (2020) Phylogenetic network analysis of SARS-CoV-2
genomes. Proceedings of the National Academy of Sciences, 10.1073/pnas.2004999117202004999.
Graham RL, Sparks JS, Eckerle LD, Sims AC, Denison MR. (2008) SARS coronavirus replicase
proteins in pathogenesis. Virus Res, 133:88-100.
Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. (2010) New algorithms and
methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst
Biol, 59:307-21.
Guo YR, Cao QD, Hong ZS, et al. (2020) The origin, transmission and clinical therapies on
coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res, 7:11.
He J, Peng G, Min J. (2004) Molecular Evolution of the SARS Coronavirus During the Course of the
SARS Epidemic in China. Science, 303:
Holder M, Lewis PO. (2003) Phylogeny estimation: traditional and Bayesian approaches. Nat Rev
Genet, 4:275-84.
Huang C, Wang Y, Li X, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus
in Wuhan, China. Lancet, 395:497-506.
Kumar S, Stecher G, Li M, Knyaz C, Tamura K. (2018) MEGA X: Molecular Evolutionary Genetics
Analysis across Computing Platforms. Mol Biol Evol, 35:1547-9.
Lam TT, Shum MH, Zhu HC, et al. (2020) Identifying SARS-CoV-2 related coronaviruses in Malayan
pangolins. Nature, 10.1038/s41586-020-2169-0
Langmead B, Salzberg SL. (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods, 9:357-9.
Lefort V, Longueville JE, Gascuel O. (2017) SMS: Smart Model Selection in PhyML. Mol Biol Evol,
34:2422-4.

19

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452

Letunic I, Bork P. (2019) Interactive Tree Of Life (iTOL) v4: recent updates and new developments.
Nucleic Acids Res, 47:W256-W9.
Li F. (2016) Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol,
3:237-61.
Li H. (2011) A statistical framework for SNP calling, mutation discovery, association mapping and
population genetical parameter estimation from sequencing data. Bioinformatics (Oxford, England),
27:2987-93.
Li H, Handsaker B, Wysoker A, et al. (2009) The Sequence Alignment/Map format and SAMtools.
Bioinformatics (Oxford, England), 25:2078-9.
Liu Y, Du X, Chen J, et al. (2020) Neutrophil-to-lymphocyte ratio as an independent risk factor for
mortality in hospitalized patients with COVID-19. J Infect, 10.1016/j.jinf.2020.04.002
Liu Y, Gayle AA, Wilder-Smith A, Rocklov J. (2020) The reproductive number of COVID-19 is higher
compared to SARS coronavirus. J Travel Med, 27:
Lu R, Zhao X, Li J, et al. (2020) Genomic characterisation and epidemiology of 2019 novel
coronavirus: implications for virus origins and receptor binding. Lancet, 395:565-74.
Malavolta M, Giacconi R, Brunetti D, Provinciali M, Maggi F. (2020) Exploring the Relevance of
Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.
Cells, 9:
Rambaut A, Lam TT, Max Carvalho L, Pybus OG. (2016) Exploring the temporal structure of
heterochronous sequences using TempEst (formerly Path-O-Gen). Virus Evol, 2:vew007.
van Dorp L, Acman M, Richard D, et al. (2020) Emergence of genomic diversity and recurrent
mutations

in

SARS-CoV-2.

Infection,

Genetics

and

Evolution,

https://doi.org/10.1016/j.meegid.2020.104351104351.
WHO. (2020) Coronavirus disease 2019 (COVID-19) Situation Report – 93. WHO,
Wrapp D, Wang N, Corbett KS, et al. (2020) Cryo-EM structure of the 2019-nCoV spike in the
prefusion conformation. Science, 367:1260-3.
Yang J, Lee SH, Goddard ME, Visscher PM. (2011) GCTA: a tool for genome-wide complex trait
analysis. Am J Hum Genet, 88:76-82.
Yu WB, Tang GD, Zhang L, Corlett RT. (2020) Decoding the evolution and transmissions of the novel
pneumonia coronavirus (SARS-CoV-2 / HCoV-19) using whole genomic data. Zool Res, 41:247-57.
Yuen K-S, Ye Z-W, Fung S-Y, Chan C-P, Jin D-Y. (2020) SARS-CoV-2 and COVID-19: The most
important research questions. Cell Biosci, 10:40.
Zhang L, Shen F-m, Chen F, Lin Z. (2020) Origin and Evolution of the 2019 Novel Coronavirus.
Clinical Infectious Diseases, 10.1093/cid/ciaa112
Zhang YZ, Holmes EC. (2020) A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.
Cell, 181:223-7.
Zhang Z, Li J, Zhao XQ, Wang J, Wong GK, Yu J. (2006) KaKs_Calculator: calculating Ka and Ks
through model selection and model averaging. Genomics Proteomics Bioinformatics, 4:259-63.
Zhao Z, Li H, Wu X, et al. (2004) Moderate mutation rate in the SARS coronavirus genome and its
implications. BMC Evol Biol, 4:21.
Zhou P, Yang XL, Wang XG, et al. (2020) A pneumonia outbreak associated with a new coronavirus of
probable bat origin. Nature, 579:270-3.
20

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

453
454

Figure Legends

455

Figure 1

456

The 622 sequences were clustered into three clusters: Cluster 1 were mainly from North America,

457

Cluster 2 were from regions all over the world, and Cluster 3 were mainly from Europe.

458

Figure 2 Linkage disequilibrium plot of haplotypes of the 9 specific sites

459

A. The plot for 622 genome sequences; B. The plot for 3624 genome sequences.

460

Figure 3

461

The frequencies of the 9 specific sites (A) and haplotypes (B) in each country for 3624 genomes.

462

Figure 4

463

A. The numbers of haplotypes of the 9 specific sites for 16373 genomes with clear collection data

464

detected in each country in chronological order; B. The whole genome mutations in each major

465

haplotype subgroup.

466

Figure 5 Phylogenetic network of haplotype subgroups for 3624 genomes

467

The network was inferred by POPART using TCS method. Each colored vertex represents a haplotype,

468

with different colors indicating the different sampling areas. Hatch marks along edge indicated the

469

number of mutations. Small black circles within the network indicated unsampled haplotypes. H1-H5

470

subgroups were point out according haplotypes of the 9 specific sites, and other small subgroups were

471

not specially pointed out.

Phylogenetic tree and clusters of 622 SARS-CoV-2 genomes

The frequencies of both the 9 specific sites and haplotypes

The characteristics of haplotype subgroups

21

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

472

Figure 6 The correlation between death rate and frequencies of both the 9 specific sites and

473

haplotypes

474
475

Tables

476

Table 1

477

MERS-CoV and SARS-CoV-2 genome sequences

478

Table 2 Substitution rate and tMRCA estimated by BEAST v2.6.2

479

Table 3 The information of the 9 specific sites in each Cluster

480

Table 4 Statistics of Ka, Ks and Ka/Ks ratios for all coding regions of each 4 major haplotype

481

subgroup with 3624 and 16373 genomes respectively

Statistics of Ka, Ks and Ka/Ks ratios for all coding regions of the SARS-CoV,

482
483

Supplementary material

484

Figure S1

485

phylogenetic tree of SARS-CoV (A), MERS-CoV (B) and SARS-CoV-2 (C)

486

The root-to-tip genetic distances were inferred in TempEst v1.5.3. Three data sets exhibit a positive

487

correlation between root-to-tip divergence and sample collecting time, and they appear to be suitable

488

for molecular clock analysis.

489

Figure S2 Substitution rate and tMRCA estimate of SARS-CoV-2

490

A. Estimated substitution rate of SARS-CoV-2 using BEAST v2.6.2 under a strict molecular clock. The

491

mean rate was 1.601 x 10-3 (substitutions per site per year). B. The estimated tMRCA of SARS-CoV-2

492

using BEAST v2.6.2 under a strict molecular clock. The mean tMRCA was 2019.74 (date:

Regression analyses of the root-to-tip divergence with the maximum-likelihood

22

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

493

2019-09-27).

494

Figure S3 Phylogenetic tree of 622 SARS-CoV-2 genomes

495

A. Phylogenetic tree constructed by PhyML with bootstrap value of 100; B. Phylogenetic tree

496

constructed by MEGA with bootstrap value of 100.

497

Figure S4 The PCAs analysis result based on the 9 specific sites (A) and all SNVs (B)

498

Table S1 The information of the first downloaded complete genome sequences

499

Table S2 The sequence IDs in each Cluster

500

Table S3 The details information of the SNVs in all Clusters

501

Table S4 The information of death rate, frequencies of the 9 specific sites and major haplotypes

502

in each country for 3624 and 16373 genomes respectively

503

Table S5 All haplotypes of the 9 specific sites and numbers of them for 3624 and 16373 genomes

504

respectively

505

Table S6 Whole genome mutations and frequencies in each major haplotype subgroup of 3624

506

and 16373 genomes respectively

23

Tree scale: 0.0001

/0 5 _ N o rth A m e rica /U S A /C a
lifo rn ia /S a n F ra n cisco

0 /0 2 /2 9 _ N o rth A m e rica
/U S A /W a sh in g to n /K in
g C o u n ty
2 0 2 0 /0 2 /2 9 _ N o rth A
m e rica /U S A /W a sh
in g to n /K in g C o u n ty
6 _ 2 0 2 0 /0 3 /0 3 _ N
o rth A m e rica /U S
A /W a sh in g to n /K
EPI_ISL_416446_2020/03/1
in g C o u n ty
0_NorthAmerica/USA/Washi
ngton
EPI_ISL_414
620_2020/03
/08_NorthAm
erica/USA
EPI_ISL_41
4592_2020/
03/06_Nort
hAmerica/U
SA/Washing
EPI_ISL_4
ton/Tacoma
15604_202
EPI.ISL.41
0/03/10_N
6465
orthAmeri
ca/USA/Washington
EPI_ISL_416465_2
EPI.ISL.41
020/02/29_NorthA
5617
merica/USA/Washi
EPI_ISL_
415617_2
EPI.ISL.4
ngton/KingCounty
020/03/0
14595
9_NorthA
EPI_ISL_414595
merica/U
SA/Washi
EPI.ISL.
_2020/03/05_No
415620
ngton
rthAmerica/USA
EPI_ISL
MT163718
_415620
/Washington/Ki
_2020/0
3/09_No
rkland
MT163718_202
rthAmer
EPI.ISL
ica/USA
.413653
0/02/29_Unit
/Washin
gton
edStates/Was
EPI_IS
EPI.ISL
L_4136
.415541
hington
53_202
0/03/0
EPI_IS
5_Nort
EPI.ISL
hAmeri
L_4155
.413563
ca/USA
41_202
/Washi
0/03/1
EPI_IS
ngton
3_Nort
MT1637
L_4135
19
hAmeri
63_202
ca/USA
0/03/0
/Utah
MT163719_2
EPI.IS
3_Nort
L.4146
hAmeri
020/03/01_
18
ca/USA
/Washi
EPI.IS
UnitedStat
EPI_I
ngton
L.4136
SL_41
es/Washing
50
4618_
2020/
EPI.IS
ton
EPI_I
03/08
L.4136
SL_41
_Nort
51
3650_
hAmer
ica/U
2020/
EPI.I
EPI_I
SA
03/05
SL.41
SL_41
_Nort
5596
3651_
hAmer
EPI.I
2020/
ica/U
EPI_ISL_
SL.41
03/05
SA/Wa
5605
_Nort
shing
415596_2
hAmer
ton
MT163
020/03/0
ica/U
EPI_ISL_
717
SA/Wa
9_NorthA
415605_2
shing
EPI.I
ton
merica/U
020/03/0
MT16
SL.41
3717
6447
SA/Wa
5_NorthA
_202
shington
EPI.I
0/02
merica/U
SL.41
EPI_
/28_
5595
ISL_
Unit
SA/Washi
4164
edSt
MT188
47_2
ates
339
ngton
EPI_
/Was
020/
ISL_
hing
03/1
4155
ton
0_No
MT188
95_2
rthA
341
MT18
020/
meri
8339
03/0
ca/U
MT15
_202
9_No
SA/W
2824
0/03
rthA
ashi
MT18
/09_
ngto
meri
8341
Unit
n
ca/U
MT16
_202
edSt
3720
SA/W
0/03
MT15
ates
ashi
/05_
2824
/MN
ngto
EPI.
Unit
_202
n
ISL.
edSt
0/02
4156
MT16
ates
/24_
06
3720
/MN
EPI.
Unit
_202
ISL.
edSt
0/03
4164
EPI_IS
ates
42
/01_
EPI.
/Was
L_4156
Unit
ISL.
hing
edSt
4165
06_202
EPI_IS
ton/
14
ates
EPI.
Snoh
0/03/0
L_4164
/Was
ISL.
omis
hing
4164
8_Nort
EPI
42_202
hCou
37
ton
_IS
EPI.
nty
hAmeri
L_4
0/03/1
ISL.
165
4164
ca/USA
EPI
0_Nort
14_
45
EPI.
_IS
202
/Washi
ISL.
L_4
hAmeri
0/0
164
4156
3/1
ngton
EPI
ca/USA
37_
5_O
15
EPI.
_IS
202
cea
ISL.
L_4
/Washi
0/0
nia
4164
164
/Au
3/1
EPI
ngton
43
45_
EPI.
str
0_N
_IS
202
ali
ISL.
ort
L_4
0/0
a/V
hAm
4164
156
3/1
ict
EPI
eri
EPI
41
15_
ori
0_N
ca/
_IS
.IS
202
a/M
ort
USA
L.4
L_4
0/0
elb
hAm
146
/Wa
164
EPI
3/0
EPI
our
21
eri
shi
43_
.IS
ne
_IS
8_N
ngt
ca/
202
L.4
ort
L_4
on
USA
0/0
156
hAm
164
/Wa
EPI
EPI
14
3/1
eri
41_
shi
.IS
_IS
0_N
ca/
L.4
ngt
202
L_4
ort
156
USA
on
0/0
EPI
146
hAm
EPI
19
/Wa
3/1
.IS
21_
eri
_IS
shi
0_N
L.4
202
ca/
ngt
L_4
155
ort
EPI
USA
0/0
on
156
94
EPI
hAm
.IS
/Wa
3/0
14_
_IS
eri
L.4
shi
8_N
202
L_4
ca/
164
ngt
EPI
ort
0/0
36
156
USA
EPI
on
.IS
hAm
3/0
/Wa
19_
_IS
L.4
eri
9_N
shi
202
145
L_4
EPI
ca/
ort
ngt
97
0/0
EPI
155
.IS
USA
on
hAm
3/0
L.4
_IS
94_
/Wa
eri
146
9_N
L_4
202
EPI
shi
ca/
17
ort
.IS
EPI
0/0
164
ngt
USA
L.4
hAm
_IS
on/
3/1
36_
/Wa
156
EPI
eri
Kir
L_4
0_N
202
shi
07
.IS
ca/
EPI
kla
ort
145
0/0
ngt
L.4
USA
nd
_IS
hAm
97_
3/1
on
156
EPI
/Wa
L_4
eri
202
0_N
16
.IS
EPI
shi
146
ca/
ort
0/0
L.4
ngt
_IS
USA
17_
hAm
3/0
164
EPI
on
L_4
/Wa
202
40
eri
.IS
4_N
EPI
156
shi
L.4
0/0
ca/
ort
_IS
EPI
ngt
164
07_
USA
3/0
hAm
L_4
.IS
54
on
202
/Wa
8_N
eri
EPI_
L.4
156
0/0
shi
ort
ca/
EPI
145
ISL_
16_
ngt
3/0
hAm
USA
.IS
93
202
on
EPI_
9_N
4164
eri
/Wa
L.4
0/0
EPI
ort
shi
155
ca/
ISL_
40_2
3/0
.IS
92
hAm
ngt
USA
EPI_
L.4
4164
8_N
020/
on/
eri
EPI
134
ort
Kir
ca/
ISL_
54_2
03/1
.IS
56
hAm
kla
USA
EPI_
L.4
4145
020/
0_No
EPI
nd
eri
/Wa
135
ISL_
.IS
93_2
ca/
shi
03/0
rthA
60
L.4
EP
USA
ngt
4155
EPI
020/
meri
6_No
I_
164
/Wa
on
.IS
IS
55
92_2
03/0
ca/U
rthA
shi
L_
L.4
EP
EPI
41
ngt
020/
164
I_
SA/Wa
5_No
meri
34
.IS
IS
on
44
56
03
rthA
L.4
L_
ca/U
shin
EP
_2
EPI
/09_
41
156
I_
02
meri
SA/W
.IS
35
gton
IS
0/
03
Nort
60
L.4
02
L_
ashi
ca/U
EP
EPI
_2
/2
41
164
hAme
I_
02
.IS
0_
64
ngto
SA/W
35
IS
0/
No
L.4
55
rica
L_
EPI
02
EP
rt
n
_2
ashi
156
41
/2
I_
.IS
hA
/USA
02
64
8_
26
IS
me
ngto
0/
L.4
44
No
EPI
L_
ri
/Was
EP
03
156
rt
_2
ca
41
n/Ki
.IS
I_
/0
hA
02
27
/U
hing
56
7_
IS
L.4
me
0/
EPI
rkla
SA
03
No
L_
EP
ri
156
03
/W
to
_2
.IS
rt
41
I_
ca
nd
/1
as
n
12
02
hA
64
L.4
IS
/U
0_
hi
EP
0/
me
35
SA
L_
EP
ng
No
I.
156
03
ri
_2
/W
41
IS
to
I_
rt
24
/1
ca
as
02
L.
n/
56
hA
IS
EP
/U
0_
41
hi
0/
Ki
26
I.
me
EP
L_
SA
No
56
ng
ng
03
IS
ri
_2
I_
41
/W
08
rt
to
Co
L.
/1
ca
EP
02
56
IS
as
hA
n
41
un
0_
I.
/U
0/
EP
27
L_
hi
me
64
ty
IS
No
SA
03
I_
_2
ng
41
33
ri
L.
rt
EP
/W
/1
to
02
IS
56
ca
41
I.
hA
as
0_
n
EP
0/
L_
12
/U
55
IS
me
hi
No
I_
91
03
SA
41
_2
L.
EP
ng
ri
rt
IS
/0
/W
41
02
56
I.
to
ca
hA
EP
56
as
9_
L_
0/
IS
24
n
/U
me
11
I_
hi
L.
No
EP
41
03
_2
SA
ri
41
ng
IS
I.
rt
56
/0
02
/W
EP
55
ca
to
IS
L_
hA
9_
08
0/
as
98
/U
L.
EP
n/
I_
me
41
No
_2
03
hi
41
I.
SA
Se
IS
ri
64
rt
02
ng
/0
56
IS
EP
at
/W
L_
ca
33
hA
to
0/
9_
21
EP
L.
tl
as
I_
/U
41
me
_2
n
03
No
I.
41
e
hi
IS
SA
55
ri
IS
56
02
rt
/0
EP
ng
L_
/W
EP
91
13
L.
ca
0/
hA
8_
I_
to
41
as
I.
41
_2
/U
03
me
No
n
IS
IS
64
hi
56
SA
02
EP
/1
ri
rt
EP
L_
L.
48
ng
11
/W
0/
I_
ca
0_
hA
I.
41
41
to
_2
as
03
/U
IS
No
IS
me
64
55
n
EP
02
hi
EP
L.
/1
SA
rt
51
ri
L_
98
I_
I.
ng
0/
41
/W
0_
hA
ca
41
_2
IS
to
03
64
IS
as
No
me
/U
56
EP
EP
L.
02
39
n/
/0
L_
hi
rt
ri
SA
I.
21
I_
41
Se
0/
9_
41
ng
hA
IS
/W
ca
56
_2
IS
at
03
EP
No
to
EP
56
L.
as
me
/U
00
02
L_
tl
I.
/1
rt
n
41
I_
13
hi
SA
ri
0/
e
IS
41
0_
56
hA
ng
/W
EP
_2
IS
ca
L.
03
EP
09
64
No
me
I.
to
as
/U
02
L_
41
/0
I_
48
rt
IS
ri
n
hi
SA
0/
56
41
EP
9_
IS
_2
L.
hA
ca
ng
EP
/W
02
03
64
I.
No
41
L_
me
02
/U
to
as
I_
IS
/0
51
56
rt
EP
41
ri
0/
SA
n
hi
L.
IS
9_
_2
22
EP
hA
I.
ca
64
/W
03
ng
40
L_
No
02
IS
I_
me
/U
as
69
39
/1
to
rt
41
L.
0/
ri
IS
73
SA
hi
1_
EP
n
_2
40
hA
56
03
ca
L_
/W
ng
No
I_
02
65
me
00
/1
/U
as
to
41
rt
0/
38
IS
EP
ri
_2
SA
0_
n
hi
56
hA
03
L_
ca
I_
02
/W
No
ng
09
me
/1
41
/U
IS
as
0/
EP
rt
to
_2
ri
0_
56
SA
hi
L_
03
n
hA
I_
ca
02
No
/W
02
ng
41
/0
me
IS
EP
/U
0/
rt
as
_2
to
56
9_
ri
L_
SA
I_
03
hA
hi
n/
02
ca
No
22
40
/W
IS
/0
ng
me
Se
0/
/U
rt
_2
as
69
8_
L_
to
ri
at
03
SA
hA
02
hi
73
No
n
40
ca
tl
/1
/W
me
0/
ng
_2
rt
/U
e
65
0_
as
ri
to
03
02
hA
SA
38
hi
No
ca
n
/0
0/
me
/W
_2
ng
rt
/U
9_
as
ri
01
02
to
hA
SA
No
hi
ca
/2
0/
n
me
rt
ng
/U
3_
01
ri
hA
to
SA
As
/2
ca
me
n
/W
ia
3_
/U
ri
as
/S
As
SA
ca
hi
in
ia
/W
/U
ng
ga
as
/C
SA
to
po
hi
hi
/W
n
re
ng
na
as
to
/G
hi
n/
ua
ng
Se
ng
to
at
do
n
tl
ng
e
6

20

E P I.IS L .4 1 6 4 4

E P I.IS L .4 1 4 6

EPI.ISL.4145
92

EPI.ISL.415
604

M N 9 8 5 3 2 5 _ 2 0 2 0 /0 1 /1 9 _ U n ite d S ta te s/W a sh in g to n /S n o h o m ish C o u n ty

E P I_ IS L _ 4 1 5 5 8 4 _ 2 0 2 0 /0 3 /0 2 _ N o rth A m e rica /C a n a d a /B ritish C o lu m b ia

E P I_ IS L _ 4 1 3 9 2 5 _ 2 0 2 0 /0 3 /0 5 _ N o rth A m e rica /U S
A /C a lifo rn ia /S a n F ra n cisco
E P I_ IS L _ 4 1 3 9 3 1 _ 2 0 2 0 /0 3 /0 5 _ N o r
th A m e rica /U S A /C a lifo rn ia /S a n F ra n
cisco

E P I_ IS L _ 4 1 3 9 2 8 _ 2 0 2 0 /0 3

E P I_ IS L _ 4 1 6 4 6 1 _ 2 0 2

E P I_ IS L _ 4 1 6 4 6 0 _

E P I_ IS L _ 4 1 6 4 6

M N 985325

E P I.IS L .4 1 5 5 8 4

E P I.IS L .4 1 3 9 3 1

E P I.IS L .4 1 3 9 2 8

E P I.IS L .4 1 6 4 6 1

E P I.IS L .4 1 6 4 6 0

E P I.IS L .4 11 0 6 0

E P I.IS L .4 1 6 0 4 2

E P I.IS L .4 0 8 4 7 8

67

a n g zh o u

090

065

E P I_ IS L _ 4 11 0 6 0 _ 2 0 2 0 /0 1 /2 1 _ A sia /C h in a /F u jia n

94

L.4

L.4

E P I_ IS L _ 4 1 6 0 4 2 _ 2 0 2 0 /0 1 /2 6 _ A sia /C h in a /H

065

.IS

.IS

E P I_ IS L _ 4 0 8 4 7 8 _ 2 0 2 0 /0 1 /2 1 _ A sia /C h in a /C h o n g q in q /Y o n g ch u a n

EPI

EPI

LC522975

China

LC522974

Chile

LC522973

Canada

M T 106054

Cambodia

40

M N 975262

L_

44

E P I.IS L .4 1 4 5 2 1

IS

99

E P I.IS L .4 0 6 5 9 3

I_

MN

n/Tokyo

EP
EP
I_
I_
IS
IS
L_
L_
41
41
49
29
41
EP
EP
80
_2
I_
I_
_2
02
IS
IS
02
EP
0/
L_
L_
0/
I_
40
01
41
78
01
IS
79
19
/3
93
L_
/1
76
26
0_
_2
41
8_
_2
_2
02
As
38
EP
As
02
0/
02
ia
I_
54
ia
0/
01
0/
/C
IS
_2
/C
/2
02
01
hi
MT
L_
02
hi
4_
/0
/2
na
40
05
0/
Oc
na
3_
4_
/S
84
04
01
ea
/H
Eu
As
ha
84
93
/3
ni
ub
ro
ia
nd
_2
_2
0_
a/
pe
ei
EP
/T
on
02
02
As
Au
67
/B
/W
I_
ai
g
0/
0/
ia
st
_2
IS
el
uh
wa
01
01
/C
ra
02
L_
gi
an
n/
/1
/3
0/
hi
li
40
um
Ta
5_
1_
01
na
a/
84
ip
/L
As
In
/2
Ne
/G
85
EP
eu
ei
ia
EP
di
3_
wS
ua
_2
I_
ve
/C
MT
I.
Un
a/
ou
ng
02
IS
n
IS
hi
04
it
Ke
th
EP
do
0/
L_
L.
na
42
ed
I.
ra
EP
Wa
01
41
ng
41
57
/S
IS
St
I_
la
le
64
/1
49
EP
_2
ic
L.
at
IS
St
41
s/
29
8_
I.
41
02
hu
EP
es
L_
at
_2
IS
Sy
As
29
0/
EP
an
I_
41
/C
L.
02
e
ia
dn
80
I.
01
/C
IS
63
al
41
0/
/C
ey
IS
/2
19
L_
EP
he
41
if
EP
02
hi
L.
8_
26
41
I_
_2
ng
or
I.
/1
40
EP
na
Un
IS
63
02
IS
du
ni
1_
79
I_
/B
it
L_
38
L.
0/
76
a/
As
IS
ei
41
41
_2
ed
02
Lo
ia
L_
MT
38
ji
64
02
St
/0
EP
sA
/V
40
05
54
ng
09
0/
at
1_
I.
ie
ng
86
04
_2
02
IS
es
As
93
tn
68
el
EP
02
L.
/0
/I
ia
EP
_2
am
MN
es
I.
40
0/
1_
/C
ll
I_
02
98
EP
/V
IS
78
02
As
hi
in
IS
0/
I_
87
EP
L.
in
93
/0
ia
na
I.
oi
L_
40
IS
01
13
hp
2_
/C
IS
84
/S
L_
41
_2
s
/2
hu
As
L.
hi
84
41
20
ha
02
4_
c
40
ia
na
46
28
0/
ng
As
84
MN
/C
EP
/S
87
_2
01
ia
ha
85
99
I_
hi
_2
ha
/2
02
MT
/V
i
44
IS
na
02
ng
1_
0/
07
ie
67
MT
L_
0/
/S
ha
Un
26
01
EP
tn
EP
04
41
02
ha
it
88
I_
/2
i
I.
42
am
30
/2
ng
IS
IS
_2
ed
57
2_
/T
15
5_
L.
ha
L_
02
EP
St
As
ha
_2
As
41
I.
41
i
0/
at
ia
nh
02
64
ia
IS
30
01
es
/H
0/
Ho
29
L.
/C
14
EP
/1
/I
on
01
a
41
hi
I.
_2
3_
ll
gK
/2
63
IS
na
02
Ne
in
41
on
3_
L.
/G
0/
EP
pa
oi
MT
No
g
41
EP
I.
ua
01
l/
s/
02
63
rt
IS
I_
ng
/2
EP
38
Ka
70
Ch
hA
L.
IS
5_
do
EPI
I_
th
62
41
me
ic
L_
EP
No
ng
IS
.IS
64
_2
ma
ri
ag
40
I_
rt
/G
L_
09
02
nd
65
ca
L.4
IS
o
hA
ua
EPI
41
0/
94
u
L_
/C
086
me
63
ng
.IS
01
_2
40
an
ri
65
zh
68
/2
90
02
L.4
ad
EP
ca
_2
ou
9_
67
0/
a/
I_IS
120
/C
02
_2
Un
01
On
MN9
0/
an
28
02
it
/1
L_
ta
01
ad
887
0/
6_
ed
4065
ri
/3
a/
01
As
St
13
o
0_
On
MT0
/2
ia
at
34_2
As
ta
9_
/C
es
EPI
726
ia
No
ri
hi
020/
/C
.IS
88
/C
rt
o
na
al
hi
L.4
hA
/G
01
if
EPI
na
me
ua
146
/22_
or
.IS
/S
ri
nd
ni
87
ca
ha
L.4
Asia
on
a
EPI
/U
ng
g/
130
SA
ha
/C
.IS
Sh
15
/M
i
hi
en
L.4
as
na/G
zh
130
sa
en
ch
14
uang
MT0
us
270
EPI
et
do
62
.IS
ts
ng/F
L.4
os
EPI
163
han
.IS
65
L.4
EP

Brazil

n g /S h e n zh e n

Belgium

h
e /G e rm a n y/M u n ic

Australia

a n g d o n g /S h e n zh e n

Other

_ U n ite d S ta te s/Te xa s

Outer Clolors: Countries

To kyo
0 /0 1 /2 9 _ Ja p a n /

H6

0/01/31_Japa
LC522974_202

H5

LC 522973_202

SouthAmerica

2 0 2 0 /0 3 /0 2 _ E u ro p

H4

1 /1 3 _ A sia /C h in a /G u a n d o

Oceania

11
M T 1 0 6 0 5 4 _ 2 0 2 0 /0 2 /

H3

u
M N 9 7 5 2 6 2 _ 2 0 2 0 /0 1 /11 _ C h in a /G

H2

NorthAmerica

E P I_ IS L _ 4 1 4 5 2 1 _

Europe

E P I_ IS L _ 4 0 6 5 9 3 _ 2 0 2 0 /0

H1

Japan/Tokyo
88
LC522975_2020/01/31_
EPI.ISL.4146
ngzhou
ngdong/Gua
932
/China/Gua
EPI.ISL.403
02/25_Asia
4688_2020/
/Shenzhen
EPI_ISL_41
/Guandong
MN938384
sia/China
0/01/14_A
03932_202
ong/Shenzhen
16377
EPI_ISL_4
EPI.ISL.4
/10_China/Guangd
nghai
MN938384_2020/01
hina/Sha
16366
7_Asia/C
EPI.ISL.4
020/02/0
hai
416377_2
a/Shang
416319
EPI_ISL_
ia/Chin
EPI.ISL.
1/30_As
_2020/0
hai
_416366
a/Shang
416318
EPI_ISL
ia/Chin
EPI.ISL.
1/28_As
_2020/0
/Shanghai
.406592
_416319
EPI.ISL
EPI_ISL
8_Asia/China
enzhen
18_2020/01/2
.413485
ong/Sh
EPI.ISL
EPI_ISL_4163
/Guand
u
/China
/Suzho
.412873
3_Asia
0/01/1
/Anhui
EPI.ISL
92_202
/China
80
L_4065
4_Asia
L.4084
EPI_IS
0/01/2
ongnam-do
EPI.IS
85_202
L_4134
a/Chungche
g
09
EPI_IS
unmin
MN9974
/SouthKore
a/Yunnan/K
02/06_Asia
51
/Chin
nix
MT0499
_Asia
/Phoe
2873_2020/
01/17
izona
2020/
EPI_ISL_41
es/Ar
43
8480_
dStat
an
MT1350
SL_40
Unite
/Yunn
EPI_I
1/22_
China
020/0
1/17_
041
ing
409_2
MT135
020/0
/Beij
MN997
951_2
China
MT049
2871
1/28_
g
SL.41
020/0
EPI.I
a/Beijin
043_2
MT135
2870
/26_Chin
SL.41
a/Seoul
EPI.I
_2020/01
3513
outhKore
MT135041
SL.41
oul
EPI.I
1_Asia/S
a/Se
Kore
3515
020/01/3
outh
a
SL.41
ia/S
Kore
EPI.I
412871_2
0_As
outh
01/3
7193
ia/S
EPI_ISL_
020/
a
SL.40
7_As
70_2
Kore
EPI.I
02/2
4128
83
outh
020/
ISL_
4129
ia/S
13_2
EPI_
o
ISL.
7_As
4135
EPI.
gi-d
02/2
ISL_
82
eong
020/
EPI_
4129
a/Gy
15_2
ISL.
en
Kore
4135
EPI.
ianm
78
outh
ISL_
ei/T
4145
ia/S
EPI_
ISL.
/Hub
5_As
EPI.
uhan
hina
01/2
77
ia/C
ei/W
020/
4145
8_As
/Hub
93_2
ISL.
lca
02/0
hina
EPI.
4071
78
020/
ISL_
ia/C
4129
hile/Ta
83_2
EPI_
7_As
ISL.
a
4129
rica/C
02/0
EPI.
79
ISL_
020/
hAme
le/Talc
4129
EPI_
82_2
ISL.
4_Sout
ca/Chi
4129
EPI.
63
ISL_
0/03/0
/Wuhan
hAmeri
4146
EPI_
ISL.
78_202
/Hubei
2_Sout
EPI.
71
han
L_4145
/Wu
0/03/0
/China
4070
bei
ISL.
EPI_IS
77_202
/Hu
7_Asia
EPI.
73
ou
ina
4070
L_4145
gzh
0/01/1
/Ch
ISL.
uan
sia
EPI_IS
78_202
g/G
8_A
EPI.
91
and
don
1/1
4146
ngl
L_4129
0/0
ang
ISL.
m/E
202
/Gu
EPI.
EPI_IS
gdo
79_
ina
and
6175
Kin
129
/Ch
ngl
ted
MT06
L_4
sia
m/E
_IS
Uni
5_A
89
gdo
EPI
pe/
146
2/2
ou
Kin
L.4
uro
0/0
gzh
ted
.IS
9_E
202
uan
33
EPI
Uni
1/2
63_
g/G
pei
163
pe/
0/0
146
don
L.4
Tai
uro
L_4
202
.IS
ang
an/
9_E
58
_IS
71_
EPI
/Gu
aiw
138
1/2
EPI
070
ou
ina
a/T
L.4
0/0
L_4
gzh
/Ch
hin
.IS
202
_IS
30
uan
EPI
sia
1_C
73_
EPI
163
hai
g/G
5_A
2/0
070
L.4
ang
don
2/2
0/0
L_4
.IS
35
/Sh
0/0
ang
202
EPI
_IS
163
g
202
ina
/Gu
75_
EPI
L.4
don
91_
/Ch
ina
661
.IS
39
ang
146
/Ch
sia
MT0
EPI
163
L_4
/Gu
sia
0_A
hai
L.4
_IS
ina
5_A
1/3
ang
.IS
EPI
23
/Ch
2/2
0/0
EPI
/Sh
163
0/0
sia
202
hai
ina
L.4
202
0_A
33_
.IS
ang
/Ch
22
89_
1/3
163
EPI
sia
/Sh
163
146
0/0
L_4
L.4
hai
2_A
ina
L_4
202
_IS
.IS
ang
2/0
/Ch
_IS
92
EPI
58_
EPI
/Sh
0/0
sia
EPI
232
138
hai
202
ina
2_A
MT1
L_4
00
ang
30_
/Ch
2/0
_IS
146
/Sh
163
sia
0/0
EPI
L.4
hai
L_4
ina
202
3_A
.IS
23
ang
_IS
/Ch
35_
2/0
EPI
146
/Sh
EPI
sia
163
L.4
0/0
ina
77
.IS
9_A
L_4
202
hou
164
EPI
/Ch
_IS
1/2
39_
ngz
L.4
sia
EPI
0/0
163
ourg
51
.IS
Gua
9_A
202
L_4
151
EPI
ng/
rasb
1/2
_IS
23_
L.4
gdo
0/0
EPI
60
163
ourg
.IS
t/St
uan
156
202
L_4
EPI
si
rasb
d-Es
a/G
L.4
22_
_IS
58
.IS
hin
bili
163
t/St
EPI
Gran
156
EPI
7_C
L_4
ia/T
L.4
d-Es
nce/
1/2
79
_IS
.IS
eorg
Gran
/Fra
0/0
145
EPI
EPI
York
L.4
202
o
ew
ia/G
rope
nce/
03
ag
/N
.IS
92_
155
ti
SA
8_As
6_Eu
/Fra
EPI
232
an
/U
L.4
o
72
/S
ca
MT1
03/0
02/2
rope
.IS
ag
ri
le
163
ti
EPI
me
020/
hi
020/
5_Eu
L.4
an
o
hA
/C
26
/S
.IS
00_2
rt
ag
77_2
ca
02/2
163
le
No
ti
ri
EPI
hi
4146
L.4
020/
4_
4164
me
an
02
/C
t
/0
hA
/S
.IS
ca
ISL_
164
an
23_2
ISL_
03
ut
le
EPI
ri
ab
0/
So
L.4
hi
EPI_
73
me
4146
EPI_
Br
02
7_
i
/C
.IS
hA
_2
rd
164
/0
ha
ca
ISL_
EPI
ut
51
oo
03
ng
ri
L.4
So
51
/N
0/
ha
5
me
i
EPI_
.IS
6_
41
02
ds
/S
hA
ha
733
/0
L_
EPI
_2
an
ut
na
ng
03
IS
000
60
60
rl
So
hi
ha
I_
0/
i
56
he
CNA
138
3_
/C
EP
/S
02
ha
41
et
/0
ia
L.4
_2
na
L_
ng
69
/N
03
As
58
hi
IS
28
.IS
ha
pe
0/
u
1_
56
41
I_
/C
/S
ro
EPI
02
ho
/0
41
L.
EP
ia
na
Eu
_2
gz
IS
02
L_
52
As
hi
79
I.
60
IS
an
0/
0_
/11_
/C
45
EP
n
10
I_
02
/H
18
/3
03
ia
41
MT
ha
EP
_2
na
07
01
0/
L_
As
Wu
72
41
hi
0/
02
IS
1_
ng
i/
L.
63
/C
96
02
_2
I_
/1
do
IS
be
41
78
ia
_2
03
EP
02
I.
l
ng
40
L_
Hu
As
26
55
EP
0/
L.
ou
ua
IS
53
a/
6_
41
63
02
IS
a
38
Se
I_
/G
in
/2
L_
41
I.
_2
41
ni
EP
a/
na
Ch
01
IS
L_
EP
02
L.
17
or
re
hi
5_
I_
0/
IS
IS
07
64
if
Ko
/C
/0
EP
02
I_
I.
41
41
st
al
th
ia
01
EP
_2
EP
L.
94
L_
oa
/C
0/
ou
As
73
IS
78
IS
dC
es
02
I.
0_
/S
40
64
I_
st
EP
16
ol
L.
_2
at
/3
ia
41
EP
oa
63
IS
/G
35
St
01
L_
As
41
I.
dC
73
nd
IS
0/
ed
0_
61
EP
L.
ol
00
I_
02
la
/3
it
ng
54
IS
/G
A0
EP
_2
ns
01
Un
41
do
I.
nd
CN
55
60
0/
ee
6_
L.
EP
st
ng
la
45
38
IS
02
Qu
/0
oa
ua
41
I.
ns
41
_2
02
a/
dC
/G
15
L.
EP
st
ee
L_
69
0/
li
ol
64
na
IS
oa
IS
Qu
28
02
ra
41
/G
I.
hi
I_
17
dC
a/
41
_2
L.
st
i
EP
nd
/C
63
EP
L_
li
IS
ol
52
Au
ha
la
ia
41
I.
IS
ra
/G
60
a/
03
ng
d
ns
As
L.
EP
I_
st
10
nd
ni
64
ha
IS
ee
an
0_
EP
Au
MT
41
ea
la
I.
/S
Qu
/3
rl
35
L.
a/
Oc
ns
EP
ht
na
05
a/
01
de
IS
ni
5_
ee
41
ec
hi
li
0/
el
I.
ne
38
ea
/0
Qu
L.
tr
/C
EP
02
ra
/G
49
ur
Oc
02
IS
a/
/U
_2
ia
st
41
ds
0_
bo
0/
I.
40
li
53
L.
Au
As
ds
an
EP
/3
02
49
el
i
ra
IS
38
a/
5_
an
rl
01
41
_2
/M
ha
st
I.
41
ni
/2
rl
L.
0/
he
18
ia
EP
Au
ng
L_
ea
i
01
IS
he
02
07
et
or
a/
ha
IS
Oc
I.
ha
0/
et
_2
41
/N
ni
ct
/S
I_
EP
5_
02
ng
L_
96
/N
pe
ea
Vi
re
EP
na
/0
_2
IS
78
ha
pe
ro
Oc
a/
po
02
hi
I_
16
40
/S
ro
Eu
8_
li
0/
ga
/C
EP
g
L_
63
Eu
na
0_
/2
ra
02
IS
in
ia
41
on
8_
hi
/1
01
_2
st
I_
L_
As
/S
nd
/0
g
/C
03
0/
17
Au
EP
IS
5_
ia
ha
03
0/
on
ia
02
07
a/
I_
/2
As
/S
0/
02
nd
As
_2
41
ni
EP
01
3_
02
na
_2
94
2_
ha
L_
ea
0/
/0
_2
61
hi
78
/0
/S
IS
Oc
02
55
02
54
40
/C
I_
02
na
8_
_2
45
41
0/
L_
ia
EP
0/
hi
/0
17
41
L_
IS
02
As
02
/C
02
63
L_
I_
IS
_2
4_
_2
ia
0/
EP
41
IS
I_
35
/2
03
As
02
I_
L_
EP
05
01
64
5_
_2
EP
IS
41
0/
41
15
/2
I_
L_
L_
02
64
01
EP
IS
IS
_2
41
0/
I_
I_
38
L_
02
EP
EP
49
IS
_2
I_
41
40
EP
L_
49
IS
41
I_
L_
EP
IS
I_
EP

Asia

E P I.IS L .4 1 3 9 2 5

Shape Plot: Haplotype

E P I.IS L .4 1 6 4 6 6

Inner Color: Continents

Cluster 1

Cluster 2

34

Denmark

Italy
Japan
Kuwait
Luxembourg
Mexico
Nepal
Netherlands
NewZealand
Poland
Portugal

Singapore
SouthKorea
Sweden

EPI.ISL.416390

EPI.ISL.414633
EPI.ISL.415654

EPI.ISL.414637

EPI.ISL.416047

Cluster 2

EPI.ISL.414632

EPI.ISL.416497

sdeFrance/Compigne
EPI_ISL_416497_2020/03/10_Europe/France/Haut
EPI.ISL.414638
nce/HautsdeFrance/Compigne
EPI_ISL_414638_2020/03/04_Europe/Fra
EPI.ISL.414626
Valois
pe/France/HautsdeFrance/Crpyen
EPI.ISL.416521
EPI_ISL_414626_2020/02/29_Euro
Asia/SaudiArabia
EPI_ISL_416521_2020/03/10_
EPI.ISL.413592
2_Asia/Taiwan/Taipei
4
EPI.ISL.41462
EPI_ISL_413592_2020/03/0
andie/Rouen
France/Norm
01
EPI.ISL.4146
/26_Europe/
624_2020/02
Rouen
EPI_ISL_414
Normandie/
494
pe/France/
EPI.ISL.416
02/27_Euro
n
4601_2020/
ndie/Roue
EPI_ISL_41
3489
nce/Norma
EPI.ISL.41
urope/Fra
0/03/04_E
16494_202
ombardy/Milan
13996
EPI_ISL_4
EPI.ISL.4
3_Europe/Italy/L
020/03/0
sin
land/Tes
12973
EPI_ISL_413489_2
/Switzer
EPI.ISL.4
4_Europe
020/02/2
bardy
413996_2
415708
EPI_ISL_
rope/Italy/Lom
EPI.ISL.
2/20_Eu
nd
_2020/0
itzerla
415601
rope/Sw
EPI_ISL_412973
EPI.ISL.
3/07_Eu
_2020/0
ngton
_415708
.414019
EPI_ISL
EPI.ISL
ca/USA/Washi
eva
0_NorthAmeri
.414020
nd/Gen
EPI.ISL
tzerla
01_2020/03/1
pe/Swi
7_Euro
eva
EPI_ISL_4156
.416489
0/02/2
nd/Gen
EPI.ISL
19_202
tzerla
L_4140
pe/Swi
81
EPI_IS
7_Euro
L.4164
ecounty
0/02/2
EPI.IS
20_202
USA/WI/Dan
L_4140
26
bilisi
EPI_IS
L.4164
hAmerican/
EPI.IS
/Georgia/T
03/15_Nort
07
03/16_Asia
pest
L.4157
6489_2020/
/Buda
EPI.IS
6481_2020/
EPI_ISL_41
ngary
04
pe/Hu
EPI_ISL_41
land
L.4157
_Euro
itzer
EPI.IS
03/17
pe/Sw
2020/
_Euro
5705
6426_
land
SL.41
03/08
SL_41
EPI.I
itzer
2020/
EPI_I
pe/Sw
5707_
5706
_Euro
SL_41
land
SL.41
03/04
EPI_I
EPI.I
2020/
/Switzer
5704_
6493
6_Europe
SL.41
SL_41
land
EPI.I
EPI_I
020/03/0
/Switzer
05_2
5652
rope
4157
SL.41
6_Eu
erry
EPI.I
-Thi
EPI_ISL_
020/03/0
teau
6499
e/Ch
SL.41
415706_2
ise
ranc
EPI.I
t/Th
sdeF
EPI_ISL_
-Com
Haut
5651
nce/
ance
SL.41
au
/Fra
e-Fr
EPI.I
jume
rope
gogn
Long
6031
8_Eu
Bour
nce/
SL.41
03/0
nce/
au
eFra
020/
EPI.I
/Fra
hate
Iled
93_2
35
rope
ux-C
nce/
4154
4164
5_Eu
ISL.
ntre
/Fra
ISL_
03/0
ulo
EPI.
EPI_
rope
t/Mo
020/
aoPa
25
1_Eu
-Com
52_2
4145
lo/S
03/1
ance
4156
ISL.
oPau
020/
e-Fr
ISL_
EPI.
ales
l/Sa
99_2
31
EPI_
gogn
om/W
razi
4146
4164
Bour
ingd
ca/B
ISL.
ISL_
nce/
nd
EPI.
meri
tedK
EPI_
/Fra
48
ngla
uthA
/Uni
rope
4136
om/E
4_So
rope
ISL.
5_Eu
ingd
03/0
6_Eu
EPI.
03/0
eims
24
tedK
020/
03/0
020/
t/R
4145
31_2
/Uni
-Es
020/
51_2
ISL.
4160
rope
4156
35_2
EPI.
/Grand
99
tugal
ISL_
ISL_
2_Eu
4154
4139
EPI_
EPI_
03/0
ISL_
France
pe/Por
ISL.
020/
EPI_
EPI.
46
and
urope/
1_Euro
25_2
ngl
4_E
4146
3/0
4145
m/E
ISL.
0/0
e
ISL_
0/03/0
gdo
EPI.
ovi
57
Kin
EPI_
48_202
Arg
4144
31_202
ted
nd/
ISL.
Uni
L_4136
d
rla
L_4146
EPI.
pe/
45
tze
lan
uro
EPI_IS
4144
EPI_IS
Swi
Fin
1_E
ISL.
pe/
pe/
3/0
EPI.
02
uro
uro
0/0
ant
7_E
4_E
4136
202
rab
2/2
3/0
24_
ISL.
rdB
0/0
0/0
145
55
nd
EPI.
Noo
202
L_4
202
156
lla
ds/
99_
_IS
46_
L.4
dHo
lan
139
EPI
.IS
146
i
Zui
her
42
L_4
EPI
L_4
ink
ds/
Net
156
_IS
_IS
els
L.4
pe/
lan
EPI
EPI
.IS
d/H
uro
her
45
EPI
lan
6_E
Net
s
140
Fin
3/0
pe/
ale
L.4
0/0
pe/
uro
.IS
i
m/W
82
202
EPI
uro
3_E
lis
gdo
164
57_
3_E
3/0
Kin
Tbi
L.4
144
3/0
0/0
.IS
ted
ia/
48
L_4
0/0
202
ro
EPI
Uni
org
146
_IS
45_
202
nei
pe/
/Ge
L.4
EPI
144
02_
eJa
uro
.IS
sia
i
01
L_4
136
iod
EPI
2_E
0_A
157
lis
_IS
L_4
o/R
3/1
3/1
L.4
Tbi
EPI
_IS
eir
0/0
.IS
0/0
55
ia/
EPI
Jan
EPI
202
202
154
org
ty
55_
ode
L.4
42_
/Ge
oun
156
/Ri
.IS
156
56
sia
goC
L_4
EPI
zil
L_4
154
nd
3_A
Die
_IS
Bra
L.4
_IS
rla
3/1
EPI
San
.IS
ca/
EPI
21
0/0
tze
EPI
ia/
eri
140
nd
202
Swi
orn
L.4
hAm
rla
82_
pe/
.IS
97
lif
out
EPI
tze
164
139
uro
/Ca
4_S
nd
L_4
L.4
Swi
2_E
3/0
USA
rla
.IS
22
_IS
pe/
0/0
3/0
ca/
EPI
140
tze
EPI
uro
202
0/0
eri
el
L.4
Swi
45_
8_E
202
hAm
Bas
24
.IS
pe/
140
2/2
ort
01_
130
EPI
nd/
L_4
uro
0/0
1_N
157
L.4
rla
_IS
eva
9_E
3/1
49
202
L_4
.IS
tze
EPI
145
0/0
2/2
EPI
_IS
55_
/Gen
Swi
L.4
202
0/0
EPI
154
eva
03
pe/
land
.IS
48_
202
L_4
en
er
157
EPI
uro
146
h
/G
56_
tz
_IS
L.4
7_E
L_4
154
EPI
98
.IS
uric
land
/Swi
2/2
_IS
156
L_4
EPI
EPI
0/0
tzer
rope
nd/Z
L.4
d
_IS
59
an
202
.IS
EPI
6_Eu
/Swi
erla
154
ll
EPI
21_
/2
pe
tz
Ho
L.4
02
ro
140
nd
rd
23
.IS
/Swi
la
oo
L_4
140
020/
7_Eu
EPI
er
/N
_IS
L.4
rope
tz
ds
97_2
57
02/2
nd
.IS
an
wi
EPI
la
9_Eu
154
rl
/S
EPI
4139
020/
er
/2
he
L.4
pe
L_
_2
02
tz
54
et
ro
IS
ve
.IS
22
wi
/N
154
Eu
en
020/
EPI
/S
pe
EPI_
1_
4140
L.4
/G
pe
ro
00
/0
d
nd
24_2
.IS
ro
Eu
03
ISL_
au
157
la
Eu
3_
EPI
0/
/V
4130
er
L.4
7_
/0
EPI_
02
58
nd
L_
tz
/2
03
.IS
nd
_2
la
IS
wi
154
02
0/
la
03
EPI
er
/S
0/
L.4
02
er
57
EPI_
tz
35
pe
02
_2
41
tz
.IS
nd
wi
ro
160
_2
49
L_
wi
la
/S
EPI
Eu
45
98
IS
L.4
/S
er
pe
29
9_
41
56
I_
pe
.IS
ro
tz
/2
nd
L_
41
160
EP
ro
Eu
wi
02
IS
EPI
la
L_
L.4
Eu
1_
05
/S
I_
0/
IS
er
9_
51
.IS
/0
EP
02
pe
I_
tz
nd
41
/2
03
_2
ro
EP
EPI
wi
la
L.
02
0/
23
59
Eu
/S
er
IS
0/
30
02
54
o
8_
I.
pe
tz
41
02
_2
41
ul
/2
EP
ro
wi
L.
_2
29
23
L_
02
Pa
Eu
IS
/S
51
57
40
IS
0/
o
ao
I.
8_
pe
41
54
I_
41
02
EP
ul
/S
/2
L.
ro
34
41
EP
L_
_2
Pa
lo
IS
02
60
Eu
L_
IS
54
na
I.
ao
au
41
0/
1_
IS
I_
EP
54
ta
L.
/S
oP
02
12
I_
EP
/0
41
IS
an
29
Sa
lo
_2
h
EP
03
I.
L_
41
eS
l/
au
00
ic
0/
EP
IS
L.
21
ad
57
zi
oP
ur
02
IS
I_
30
41
ir
ra
Sa
_2
/Z
I.
41
EP
L_
/B
Fe
l/
58
EP
nd
L.
47
nd
IS
ca
a/
zi
54
IS
36
la
la
I_
ri
hi
ra
I.
41
41
er
o
ng
EP
me
EP
75
Ba
/B
L.
L_
tz
ul
/E
64
IS
hA
ca
l/
IS
wi
Pa
41
I.
om
ut
ri
I_
zi
/S
ao
02
EP
L.
gd
So
EP
me
ra
g
pe
57
IS
/S
5_
in
hA
/B
41
h
I.
ro
er
lo
/0
dK
ut
ca
68
L.
EP
ic
Eu
mb
au
03
te
So
64
ri
IS
9_
ur
te
oP
0/
41
ni
4_
I.
me
/2
/Z
l
rt
28
Sa
02
L.
EP
/0
/U
hA
02
60
nd
ga
ue
IS
_2
l/
03
pe
ut
41
0/
I.
la
35
-W
tu
zi
0/
ro
So
43
L.
EP
02
60
er
n
en
or
ra
02
46
Eu
4_
IS
_2
41
tz
ad
ve
/P
_2
/B
41
/0
9_
I.
23
97
L_
L.
wi
/B
29
eu
ca
pe
EP
03
/2
nd
54
30
IS
IS
60
/S
ny
ri
/L
ro
0/
02
41
la
I_
41
I.
41
ma
41
pe
me
02
Eu
um
0/
L.
EP
EP
L_
er
L_
46
k
er
ro
_2
hA
02
1_
gi
IS
IS
tz
IS
41
05
ee
/G
ut
Eu
I.
_2
/0
el
68
I_
L.
wi
I_
51
EP
pe
So
9_
sb
o
29
03
54
/B
EP
IS
EP
/S
41
4_
ro
/2
51
41
ol
ul
0/
pe
I.
54
pe
L_
/0
L.
Eu
41
02
/H
Pa
02
ro
EP
45
IS
ro
IS
03
5_
L_
nd
0/
um
_2
ao
Eu
41
I_
I.
Eu
0/
IS
/2
02
la
gi
L.
47
/S
3_
EP
EP
2_
02
I_
02
_2
IS
in
36
el
/0
lo
ds
EP
_2
/0
0/
I.
21
/F
41
/B
03
au
an
34
EP
02
03
30
L_
pe
pe
0/
oP
rl
60
nd
_2
0/
41
IS
ro
ro
02
Sa
41
he
12
la
02
L_
I_
_2
Eu
Eu
l/
L_
29
et
IS
in
_2
EP
ds
75
2_
7_
zi
IS
41
/N
I_
02
/F
an
64
/0
/0
I_
ra
L_
EP
pe
57
ht
pe
41
rl
03
03
EP
/B
IS
41
ro
ec
ro
L_
0/
he
0/
I_
ca
L_
Eu
tr
Eu
IS
02
et
02
EP
ri
IS
9_
/U
5_
I_
_2
/N
_2
me
I_
/0
EP
/0
ds
68
43
pe
hA
EP
03
03
an
64
46
ro
ut
0/
0/
rl
41
41
So
Eu
02
02
L_
he
L_
3_
0_
_2
IS
_2
et
IS
/0
/1
97
I_
41
/N
I_
03
03
54
EP
46
pe
EP
0/
0/
41
41
ro
02
02
L_
L_
_2
Eu
_2
IS
IS
28
8_
68
I_
I_
60
/0
54
EP
EP
41
03
41
L_
0/
L_
IS
02
IS
I_
_2
I_
EP
54
EP
45
41
L_
IS
I_
EP

EPI.ISL.416355
MT019530

EPI_ISL_408976_2020/01/22_Oceania/Australia/NewSouthWales/Sydney

EPI_ISL_416390_2020/01/31_Asia/China/Shanghai
EPI_ISL_416047_2020/02/02_Asia/China/Hangzhou
EPI_ISL_416355_2020/02/04_Asia/China/Shanghai
MT019530_2019/12/30_China/Hubei/Wuhan

MT159718

MT159718_2020/02/18_UnitedStates

EPI.ISL.413594
EPI.ISL.413596

MT184910
MT184908

EPI.ISL.41053
1

EPI.ISL.4119

02

EPI_ISL_413594_2020/02/28_Oceania/Au
stralia/NSW/Sydney
EPI_ISL_413596_2020/02/28_Ocea
nia/Australia/NSW/Sydney
MT184910_2020/02/18_United
States
MT184908_2020/02/21_Unit
edStates

EPI_ISL_410

531_2020/01

/25_Asia/Ja

EPI_ISL_41
1902_2020/

pan/Nara

01/27_Asia
/Cambodia/
Sihanoukvi
lle
20/01/01_
China/Hub
ei/Wuhan
2019/12/30_China
/Hubei/Wuhan
020/01/2
3_Asia/C
hina/Cho
ngqing/Z
_2020/01/28_As
hongxian
ia/Taiwan/Taip
ei
0_2019/
12/30_C
hina/Hu
bei/Wuh
0/01/25_Japa
an
n/Aichi
MT0442
EPI.ISL
58_202
.414500
0/01/2
7_Unit
EPI_IS
edStat
MT15971
es/Cal
L_4145
6
iforni
00_202
a
0/03/0
MT159716_2
4_Euro
EPI.IS
L.4145
pe/Uni
020/02/24_
51
tedKin
gdom/E
UnitedStat
EPI_ISL_41
EPI.IS
ngland
L.4135
/Yorks
es
4551_2020/
73
hire/S
heffie
EPI.IS
03/07_Euro
EPI_I
ld
L.4155
SL_41
pe/Netherl
10
3573_
2020/
EPI.IS
ands/Utrec
EPI_I
03/02
L.4135
SL_41
_Euro
ht
77
5510_
pe/Ne
therl
2020/
EPI.I
EPI_I
ands/
03/09
SL.41
SL_41
Hardi
_Euro
4452
3577_
nxvel
pe/Ne
EPI.I
dGies
2020/
therl
EPI_ISL_
SL.41
senda
03/02
ands/
5505
m
_Euro
Noord
414452_2
pe/Ne
Braba
EPI.I
020/03/0
therl
nt
EPI_ISL_
SL.41
ands/
5479
6_Europe
415505_2
Naard
EPI.I
en
/Netherl
020/03/1
EPI_
SL.41
ISL_
4539
ands/Noo
1_Europe
4154
EPI.I
79_2
rdBraban
/Netherl
SL.41
EPI_
020/
4537
ISL_
03/0
t
ands/Noo
4145
8_Eu
EPI.I
39_2
rope
SL.41
rdBraban
EPI_
/Net
020/
4544
ISL_
herl
03/0
t
4145
ands
8_Eu
EPI.I
37_2
rope
SL.41
EPI_
020/
/Net
4536
ISL_
03/0
herl
EPI.
4145
8_Eu
ands
ISL.
44_2
rope
/Noo
EPI_
4155
020/
rdBr
/Net
ISL_
06
03/0
aban
herl
EPI.
4145
9_Eu
t
ISL.
ands
36_2
EPI_
4155
rope
/Noo
020/
00
ISL_
/Net
rdBr
EPI.
03/0
herl
4155
aban
ISL.
8_Eu
ands
t
06_2
4155
EPI_
rope
/Noo
020/
01
ISL_
/Net
MT18
rdBr
03/1
4155
8340
herl
aban
1_Eu
00_2
EPI_IS
ands
t
rope
020/
/Noo
EPI.
/Net
L_4155
03/1
rdBr
ISL.
herl
aban
0_Eu
4138
01_202
MT1883
ands
57
t
rope
EPI.
/Noo
0/03/11
40_202
/Net
ISL.
rdBr
herl
4146
EPI
0/03/0
aban
_Europ
92
ands
_IS
EPI.
t
L_4
/Noo
7_Unit
e/Neth
ISL.
138
rdBr
4160
EPI
erland
edStat
57_
44
aban
EPI.
_IS
202
t
ISL.
L_4
s/Noor
es/MN
0/0
146
4157
1/3
EPI
dBraba
92_
1_A
11
MN90
_IS
202
sia
8947
nt
L_4
0/0
/Ch
160
2/2
ina
EPI
EPI.
44_
/Gu
5_A
_IS
202
ISL.
ang
sia
L_4
0/0
don
/Ch
4160
157
1/2
g
MN9
ina
EPI
46
11_
5_A
/Gu
089
.IS
202
sia
ang
L.4
47_
0/0
164
/Ch
don
201
EPI
1/2
MT1
25
ina
g/G
9/1
597
2_A
_IS
/Ha
uan
2/3
09
sia
L_4
gzh
ngz
0_C
/Ch
160
ou
hou
MT1
EPI
hin
ina
46_
597
_IS
a/H
/Ha
20
202
L_4
ube
ngz
0/0
MT1
164
i/W
MT1
hou
1/2
597
25_
uha
597
06
4_A
202
n
09_
sia
MT1
0/0
202
MT1
/Ch
597
2/0
0/0
597
ina
07
3_A
2/2
20_
/Ha
MT1
sia
0_U
202
ngz
MT1
597
/Ch
nit
hou
0/0
597
08
ina
edS
2/2
06_
MT1
/Ha
tat
1_U
MT1
202
597
ngz
es
nit
12
597
0/0
hou
edS
07_
MT1
2/1
tat
597
MT1
7_U
202
15
es
597
nit
0/0
MT1
08_
edS
2/1
597
MT1
202
tat
7_U
19
597
es
0/0
nit
MN9
12_
2/1
edS
886
MT1
202
7_U
tat
68
597
0/0
es
nit
MT0
15_
2/2
195
edS
MT1
202
29
5_U
tat
597
MT0
0/0
nit
es
19_
195
2/2
edS
MN98
31
202
4_U
tat
MT0
8668
0/0
nit
es
195
2/1
MT01
edS
_202
33
8_U
MT0
tat
9529
0/01
nit
195
es
MT01
32
_201
edS
/02_
EPI
tat
9531
9/12
Chin
.IS
es
MT
L.4
_201
/23_
a/Hu
EPI
01
105
95
.IS
9/12
37
Chin
bei/
33
L.4
MT
_2
EPI
/30_
Wuha
a/Hu
01
079
02
.IS
95
87
0/
Chin
n
bei/
32
L.4
01
EP
EPI
_2
/0
084
I_
a/Hu
Wuha
01
.IS
1_
IS
31
9/
Ch
L.4
L_
bei/
n
EP
12
MT0
in
41
163
I_
/3
a/
Wuha
661
05
IS
0_
37
Hu
37
76
Ch
L_
be
EP
EPI
n
_2
in
40
i/
I_
02
.IS
a/
79
Wu
IS
0/
Hu
L.4
87
ha
L_
EPI
02
EP
be
_2
n
110
40
/0
I_
.IS
i/
02
66
84
9_
IS
Wu
0/
L.4
31
As
EPI
L_
ha
MT
01
120
ia
_2
n
41
.IS
06
/2
/S
02
26
63
5_
61
L.4
in
0/
EPI
37
As
76
EP
ga
039
01
_2
.IS
ia
_2
I_
po
/2
63
02
/S
02
L.4
IS
re
9_
EP
0/
in
0/
L_
EP
Eu
I.
163
02
ga
02
IS
41
I_
ro
21
/0
po
/0
L.
10
pe
IS
EP
re
4_
40
5_
66
I.
/F
EP
L_
As
65
Ch
IS
_2
ra
I_
41
31
ia
L.
in
nc
02
MT
20
IS
/C
40
a/
02
e/
0/
EP
26
L_
hi
39
70
Ta
Il
01
I_
_2
40
36
na
64
iw
EP
e/2
IS
02
39
/S
I.
an
de
2_
EP
0/
L_
63
ha
IS
/T
-F
As
I_
02
ng
41
_2
L.
ai
MT
ra
ia
IS
ha
/2
411
63
02
15
pe
nc
/C
EP
i
3_
L_
97
0/
21
i
95
e/
hi
I_
17
As
MT
40
01
_2
2
Pa
na
IS
18
ia
65
/1
02
ri
/F
MT
49
L_
/C
31
s
3_
0/
uj
11
EP
02
hi
40
As
_2
01
I.
ia
70
na
39
ia
02
/2
IS
EP
n
64
/A
36
/T
0/
8_
EP
L.
I_
_2
nh
_2
ha
I.
41
01
As
IS
ui
02
IS
63
il
02
ia
/2
MT
L_
/H
MT
97
L.
0/
an
0/
/C
2_
15
41
15
ef
41
01
d/
01
hi
As
97
97
19
64
ei
/2
No
MT
/1
na
ia
MT
17
05
01
52
nt
9_
18
/S
7_
/C
15
_2
_2
ha
Un
ha
49
97
As
hi
02
EP
02
EP
bu
22
it
ng
ia
11
na
0/
I.
I_
0/
ri
ha
ed
_2
/G
/C
02
IS
IS
01
i
St
ua
hi
02
MT
EP
L.
/1
/2
L_
at
ng
na
18
0/
I_
41
7_
4_
41
49
es
do
/G
55
02
IS
MT
Un
As
MT
12
63
ng
/C
ua
39
/1
L_
18
it
ia
15
97
/Z
al
ng
7_
49
41
ed
/C
hu
EP
97
_2
if
do
13
Un
MT
64
St
hi
I.
ha
or
ng
02
05
it
15
01
at
IS
na
i
/Z
ni
0/
_2
EP
ed
97
L.
_2
es
/J
EP
hu
a
02
02
I.
St
40
22
02
ia
ha
I_
IS
/0
0/
at
84
EP
_2
0/
ng
i
L.
IS
2_
02
81
MT
es
I.
02
02
su
41
L_
As
/1
IS
18
63
0/
/0
41
ia
L.
7_
49
42
MT
02
2_
41
/C
55
Un
12
18
As
/2
64
hi
39
it
_2
ia
1_
32
49
EP
na
_2
ed
02
/C
Un
13
I_
/S
02
St
0/
hi
it
_2
ha
IS
0/
EP
at
02
na
ed
02
ng
L_
03
es
I_
/1
/S
St
0/
ha
40
/1
IS
EP
ha
7_
at
i
02
84
3_
L_
I_
ng
Un
es
/2
No
81
41
ha
IS
it
4_
rt
_2
63
i
L_
ed
Un
hA
02
42
St
41
it
me
0/
_2
at
64
ed
ri
01
02
es
32
St
ca
/1
0/
_2
at
/U
8_
02
02
es
SA
As
/0
0/
/U
ia
4_
03
ta
/C
As
/0
h
hi
ia
7_
na
/C
As
/C
hi
ia
ho
na
/S
ng
/S
au
qi
ha
di
ng
ng
Ar
ha
ab
i
ia
/R
iy
ad
h

Cluster 3

NMDC6001300

2-09

NMDC60013

002-09_20

NMDC600130

02-08

EPI.ISL.4
08479

EPI.ISL.4

11927

NMDC6001

3002-10

LC521925

MT04425

227

389

12872

16336

414467

E P I.IS L .4 0 4

EPI.ISL.416

79

6399
EPI.ISL.41

EPI.ISL.4

EPI.ISL.4

MN996529

EPI.ISL.

MT039873

MN996530

EPI.ISL.416370

E P I.IS L .4 1 6 3

E P I.IS L .4 1 4 4 9 9

E P I.IS L .4 1 3 4 8 8

o n th a b u ri

u b e i/W u h a n

g /H a n g zh o u

ia /C h in a /H u b e i/Jin g zh o u

b e i/W u h a n

/0 7 _ C h in a /H u b e i/W u h a n

S hanghai
1 _ A sia /C h in a /

9 /1 2 /3 0 _ A sia /C h in a /H

/2 0 _ C h in a /Z h e jia n

u
/1 2 /3 0 _ C h in a /H

7 0 _ 2 0 2 0 /0 2 /0

01
M T 039873_2020/

9
M N 996530_201

E P I_ IS L _ 4 1 6 3

E P I_ IS L _ 4 1 6

E P I_ IS L _ 4 1 4 4 9 9 _ 2 0 2 0 /0 2 /2 6 _ E u ro p e /G e rm a n y/N o rth R h in e W e stp h a lia /H e in sb e rg D istrict

n sb e rg D istrict
E P I_ IS L _ 4 1 3 4 8 8 _ 2 0 2 0 /0 2 /2 8 _ E u ro p e /G e rm a n y/N o rth R h in e W e stp h a lia /H e i

E P I_ IS L _ 4 0 3 9 6 2 _ 2 0 2 0 /0 1 /0 8 _ A sia /T h a ila n d /N

E P I_ IS L _ 4 1 2 4 5 9 _ 2 0 2 0 /0 1 /0 8 _ A s

/0 1
N M D C 6 0 0 1 3 0 0 2 -0 7 _ 2 0 2 0

E P I_ IS L _ 4 0 2 1 3 2 _ 2 0 1

Vietnam

EPI.ISL.408976

EPI.ISL.415648

EPI_ISL_414637_2020/03/04_Europe/France/HautsdeFrance/Compigne

E P I.IS L .4 0 3 9 6 2

UnitedStates

EPI_ISL_414684_2020/02/27_Asia/China/Guangdong/Guangzhou

E P I.IS L .4 1 2 4 5 9

UnitedKingdom

MT093631_2020/01/08_China

EPI.ISL.414684

N M D C 6 0 0 1 3 0 0 2 -0 7

Thailand

EPI_ISL_411950_2020/01/23_Asia/China/Jiangsu

MT093631

E P I.IS L .4 0 2 1 3 2

Taiwan_China

/Jiangxi/Pingxiang
EPI_ISL_408486_2020/01/11_Asia/China
i
EPI_ISL_416340_2020/02/02_Asia/China/Shangha

EPI.ISL.411950

EPI.ISL.408486

.413582
EPI.ISL

Switzerland

es/California

MT106053_2020/02/10_UnitedStat

EPI.ISL.416340

EPI_ISL_415654_2020/03/09_Europe/France/HautsdeFrance/Compigne

EPI_ISL_414632_2020/03/04_Europe/France/Grand-Est/Reims

MT106053

s
ri
Pa
s
e/
ri
nc
Pa
s
ra
e/
ri
-F
nc
Pa
de
ra
e/
e-F
nc
Il
de
ra
e/
ewa
-F
nc
Il
ga
de
ra
e/
ena
/F
nc
Il
Ka
pe
ra
e/
n/
ro
/F
nc
pa
Eu
pe
ra
Ja
9_
g
ro
/F
0_
/2
on
Eu
pe
/1
gK
01
2_
g
ro
02
on
0/
/0
on
Eu
0/
/H
02
02
gK
9_
02
ia
re
_2
0/
on
/2
n
_2
po
As
30
02
/H
01
ha
ga
2_
32
84
ia
_2
0/
os
in
/2
82
40
As
18
n
02
/F
/S
02
52
yo
L_
1_
12
ha
_2
ng
ia
0/
ok
LC
IS
wa
/0
41
os
do
84
As
/T
02
I_
ga
02
/F
L_
ng
09
1_
an
_2
na
EP
ng
0/
IS
ua
41
/0
ap
71
do
Ka
02
I_
/G
L_
02
/J
45
ng
n/
_2
na
EP
IS
0/
ia
41
ua
pa
30
hi
02
I_
As
L_
/G
Ja
20
/C
0_
_2
30
EP
IS
na
32
0_
ia
41
84
/2
88
re
82
hi
I_
/1
As
L_
40
02
79
po
52
/C
18
EP
02
2_
L.
IS
0/
LC
ga
40
12
ia
IS
0/
/2
I_
02
in
41
L_
As
I.
02
01
84
EP
e
L.
/S
_2
IS
2_
EP
09
_2
0/
in
IS
at
ia
59
I_
/2
41
33
02
I.
ns
i
St
71
As
34
L.
01
EP
EP
co
_2
ha
82
la
45
2_
IS
41
0/
is
ng
35
41
52
ra
I.
/0
L_
02
30
L.
ha
/W
i
65
Ke
LC
EP
02
IS
20
_2
IS
/S
ha
es
a/
40
0/
41
I_
I.
36
ng
na
at
di
L_
88
L.
02
EP
EP
65
ha
hi
St
u
79
In
IS
IS
_2
40
/S
/C
ed
40
ho
I.
7_
I_
19
L.
na
L_
ia
gz
it
EP
/2
EP
ey
07
IS
hi
As
IS
an
Un
u
01
dn
41
I.
/C
2_
Gu
I_
1_
ho
0/
ey
59
Sy
33
EP
L_
ia
g/
/0
EP
/3
gz
34
dn
82
02
W/
IS
ey
As
on
02
an
01
41
Sy
52
NS
_2
dn
I_
9_
gd
0/
L.
35
Gu
LC
s/
0/
a/
98
Sy
EP
65
IS
/2
an
02
g/
le
02
li
20
W/
40
I.
Gu
01
Wa
on
_2
ra
_2
NS
01
L.
EP
36
a/
0/
th
gd
98
st
87
a/
IS
65
MT
ou
in
02
an
63
Au
98
I.
40
li
wS
Ch
_2
Gu
ne
41
a/
EP
L.
03
19
ra
Ne
9_
ur
a/
24
ni
IS
L_
07
st
MT
a/
bo
/2
in
63
I.
ea
41
IS
Au
li
el
EP
01
Ch
L.
41
Oc
I_
a/
nd
ra
/M
IS
0/
9_
L_
2_
EP
ni
la
st
ia
I.
/2
02
li
/0
IS
ea
rk
EP
Au
or
98
01
wa
_2
03
ey
I_
Ki
Oc
ct
a/
20
Ha
0/
dn
93
0/
n/
EP
8_
01
Vi
ni
t/
Sy
02
32
02
to
/2
MT
a/
87
ea
98
s/
ai
_2
ng
_2
12
02
98
li
Oc
63
le
uw
hi
91
97
MT
0/
03
ra
9_
41
Wa
/K
as
32
MT
35
02
st
L.
/2
th
24
ia
/W
41
12
IS
_2
Au
02
63
ou
As
SA
I.
L_
MT
a/
95
41
0/
wS
/U
2_
EP
ni
IS
L.
35
ey
Ne
02
ca
/0
IS
ea
dn
I_
41
a/
_2
ri
03
I.
Sy
Oc
EP
L_
li
13
me
0/
EP
nd
W/
2_
93
ra
IS
32
hA
02
la
NS
/0
st
I_
232
41
rt
_2
ol
a/
03
Au
EP
L_
No
58
dH
MT1
li
0/
a/
91
6_
IS
ui
97
64
ra
02
ni
232
/0
I_
/Z
41
st
135
ea
_2
03
ds
EP
and
Au
L_
MT1
Oc
12
L.4
0/
an
a/
IS
95
8_
64
y
rl
02
uckl
.IS
ni
I_
/2
41
135
he
_2
ea
EPI
EP
02
L_
ydne
nd/A
et
L.4
dney
91
Oc
0/
13
IS
/N
45
3_
.IS
02
es/S
I_
eala
W/Sy
pe
132
41
/0
_2
EPI
EP
ro
L_
03
L.4
75
a/NS
NewZ
thWal
58
0/
IS
.IS
29
6_Eu
02
164
I_
41
rali
nia/
wSou
EPI
/0
_2
EP
L.4
st
L_
ea
Ne
03
00
12
IS
.IS
0/
36
a/Au
164
lia/
7_Oc
I_
02
rk
EPI
41
EP
_2
L.4
L_
wYo
eani
stra
02/2
91
58
.IS
IS
and
/Ne
45
145
I_
EPI
4_Oc
a/Au
020/
41
ngl
USA
L.4
EP
L_
75
m/E
eani
03/0
ca/
.IS
90_2
IS
129
gdo
EPI
I_
a
eri
9_Oc
020/
4134
L.4
EP
Kin
mbi
hAm
00
.IS
02/2
99_2
ch
ted
ISL_
olu
ort
136
EPI
uni
Uni
shC
020/
L.4
9_N
4135
EPI_
y/M
58
iti
pe/
.IS
2/2
14_2
ISL_
145
man
/Br
EPI
uro
0/0
L.4
Ger
ada
4132
8_E
EPI_
202
90
.IS
Can
pe/
2/2
76_
ISL_
134
EPI
ca/
uro
0/0
L.4
144
EPI_
eri
2_E
hai
202
99
.IS
L_4
hAm
3/0
ang
135
EPI
22_
_IS
ort
L.4
/Sh
0/0
145
EPI
.IS
14
1_N
ina
202
hai
L_4
EPI
132
3/0
/Ch
20_
ang
_IS
L.4
0/0
sia
/Sh
145
EPI
.IS
76
0_A
202
ina
L_4
hai
EPI
144
1/3
81_
/Ch
_IS
ang
L.4
0/0
sia
155
.IS
/Sh
EPI
22
202
7_A
L_4
EPI
ina
145
hai
32_
2/0
_IS
L.4
/Ch
ang
.IS
0/0
163
EPI
sia
20
/Sh
EPI
202
L_4
145
8_A
ina
hai
L.4
73_
_IS
2/0
/Ch
ang
.IS
163
EPI
81
0/0
sia
EPI
/Sh
155
L_4
202
han
5_A
ina
L.4
_IS
82_
/Wu
2/1
/Ch
.IS
and
32
bei
EPI
163
0/0
EPI
sia
ngl
163
/Hu
L_4
202
5_A
m/E
L.4
ina
_IS
06_
2/1
gdo
.IS
/Ch
73
EPI
164
ao
EPI
Kin
0/0
163
sia
ngd
L_4
ted
202
L.4
8_A
/Qi
_IS
Uni
07_
.IS
1/1
ong
82
EPI
pe/
EPI
164
0/0
163
and
uro
L_4
L.4
202
/Sh
7_E
_IS
.IS
81_
ina
06
2/2
EPI
EPI
uan
129
/Ch
164
0/0
aoy
L_4
sia
L.4
202
n/T
.IS
9_A
_IS
08_
07
iwa
EPI
1/1
EPI
140
164
/Ta
uan
k
0/0
L.4
L_4
sia
wij
202
.IS
_IS
n/Taoy
ter
6_A
82_
81
EPI
EPI
Ois
2/2
084
4129
/Taiwa
ds/
0/0
L_4
ISL.
sia
lan
202
_IS
her
7_A
EPI.
08
41_
EPI
Net
2/2
4140
157
pe/
0/0
L_4
ISL.
uro
202
abant
_IS
EPI.
82
2_E
43_
EPI
4084
3/0
uhan
oordBr
157
0/0
ISL.
L_4
202
ands/N
ubei/W
EPI.
_IS
41
80_
EPI
4157
etherl
hina/H
135
ISL.
e/N
i
0_C
L_4
EPI.
_IS
43
ngha
_Europ
9/12/3
EPI
4157
/Sha
ISL.
hina
31_201
0/03/11
ng
EPI.
80
ia/C
ngdo
MN9965
16_202
4135
8_As
/Gua
ISL.
01/2
L_4155
hina
EPI.
i
020/
ia/C
ngha
EPI_IS
20_2
9_As
zhou
6531
/Sha
4163
02/0
uang
MN99
hina
ISL_
16
020/
ng/G
ia/C
4155
EPI_
64_2
ngdo
8_As
ISL.
4138
/Gua
EPI.
02/0
20
hina
ISL_
020/
4163
i
ia/C
EPI_
63_2
ISL.
ngha
2_As
4163
EPI.
/Sha
01/2
64
ISL_
hina
020/
4138
EPI_
ia/C
33_2
ISL.
1_As
EPI.
4065
02/0
63
ISL_
4163
020/
EPI_
ISL.
oto
u
61_2
EPI.
n/Ky
gzho
4163
Japa
Guan
6533
ISL_
/29_
ong/
EPI_
SL.40
angd
0/01
EPI.I
a/Gu
_202
nghai
6361
Chin
2972
SL.41
/05_
LC52
hina/Sha
0/02
EPI.I
_202
1_Asia/C
nghai
3290
972
MT12
020/02/0
hina/Sha
zhou
LC522
/Hang
416387_2
4_Asia/C
jiang
290
EPI_ISL_
a/Zhe
020/02/0
MT123
/Chin
416353_2
_Asia
6387
nghai
SL.41
01/19
EPI_ISL_
a/Sha
EPI.I
2020/
/Chin
7313_
6353
_Asia
SL_40
SL.41
02/05
nghai
EPI_I
EPI.I
a/Sha
2020/
/Chin
6376_
13
_Asia
SL_41
L.4073
02/02
EPI_I
EPI.IS
nghai
2020/
a/Sha
76
6362_
n
L.4163
SL_41
_Asia/Chin
EPI.IS
EPI_I
02/02
ngsu/Huaia
2020/
62
6405_
/China/Jia
nd
L.4163
SL_41
dHolla
EPI.IS
EPI_I
01/19_Asia
ds/Zui
herlan
05
8488_2020/
L.4164
pe/Net
EPI.IS
3_Euro
terdam
EPI_ISL_40
0/03/0
ds/Rot
63_202
herlan
.408488
L_4145
pe/Net
EPI.ISL
1_Euro
EPI_IS
dHolland
0/03/0
82_202
.414563
herlands/Zui
L_4135
EPI.ISL
EPI_IS
5_Europe/Net
67_2020/03/0
an
bei/Wuh
EPI_ISL_4144
hina/Hu
12/30_C
hai
9_2019/
MN99652
ia/China/Shang
gi-do
_2020/02/01_As
a/Gyeong
outhKore
EPI_ISL_416336
1_Asia/S
020/02/0
412872_2
EPI_ISL_
hina/Shanghai
020/02/13_Asia/C
EPI_ISL_416399_2
/Shanghai
sia/China
0/01/21_A
16389_202
jiang
EPI_ISL_4
/China/Zhe
01/16_Asia
4227_2020/
i
EPI_ISL_40
in a /S h a n g h a
/0 1 _ A sia /C h
3 7 9 _ 2 0 2 0 /0 2

SaudiArabia

EPI_ISL_415648_2020/03/03_Europe/Italy

EPI_ISL_414633_2020/03/04_Europe/France/Ile-de-France/Pontoise

NMDC60013002-06

EPI.ISL.415649

EPI.ISL.413572

EPI.ISL.416478

E P I.IS L .4 1 5 6 5 7

Ireland

EPI_ISL_416478_2020/03/14_Asia/Georgia/Tbilisi

E P I.IS L .4 1 5 9 2 0

India

EPI_ISL_413572_2020/03/01_Europe/Netherlands/Haarlem

E P I_ IS L _ 4 1 5 6 5 7 _ 2 0 2 0 /0 3 /1 2 _ E u ro p e /U n ite d K in g d o m /W a le s

Hungary

E P I_ IS L _ 4 1 5 9 2 0 _ 2 0 2 0 /0 3 /1 2 _ E u ro p e /U n ite d K in g d o m /W a le s

Germany
HongKong_China

4164

EP
I_
EP
IS
I_
EP
EP
L_
EP
IS
I_
I_
41
I_
IS
L_
IS
54
IS
L_
41
L_
82
L_
41
44
41
_2
41
35
35
54
44
02
84
_2
71
29
0/
_2
02
_2
_2
02
03
0/
02
02
0/
/0
03
0/
0/
EP
03
9_
/0
03
EP
03
I_
/0
3_
Eu
/1
EP
I_
/0
IS
3_
Eu
ro
EP
1_
I_
IS
2_
L_
Eu
I_
ro
pe
Eu
IS
L_
Eu
41
ro
IS
pe
/N
ro
L_
41
54
ro
pe
L_
/N
et
pe
41
36
67
pe
41
/N
et
he
45
/N
04
_2
L_
/N
45
et
he
rl
52
et
_2
41
02
et
62
he
rl
_2
an
he
02
45
0/
he
_2
rl
an
02
ds
0/
rl
45
03
02
rl
an
ds
0/
03
_2
an
0/
/1
an
ds
03
/U
/0
02
ds
03
0_
ds
/R
/0
tr
0/
3_
/0
Eu
EP
/N
ot
7_
ec
03
Eu
3_
I_
ro
oo
te
Eu
ht
/0
ro
Eu
IS
EP
pe
rd
rd
ro
3_
EP
pe
ro
I.
L_
/N
Br
pe
am
Eu
I_
IS
/F
pe
41
et
ab
EP
/N
L.
ro
IS
in
54
/N
he
I.
an
et
41
L_
pe
EP
la
75
et
IS
rl
t
EP
54
he
EP
41
I_
/N
_2
nd
L.
he
an
82
I_
I.
rl
IS
54
et
41
02
rl
/H
IS
ds
IS
EP
L_
76
an
54
he
0/
EP
an
el
L.
L_
I_
71
41
_2
ds
rl
I.
03
ds
si
41
41
IS
64
02
IS
/U
an
/1
44
/Z
nk
64
L_
EP
EP
L.
30
EP
0/
tr
ds
35
2_
ui
28
i
I.
41
I_
41
I_
_2
03
/N
ec
Eu
IS
dH
60
_2
35
IS
IS
02
/1
EP
oo
ht
L.
ro
36
02
ol
84
L_
L_
0/
I.
0_
41
rd
pe
_2
0/
la
EP
41
41
IS
03
Eu
44
Br
02
/N
03
EP
I_
nd
64
L.
30
/0
29
ro
0/
ab
et
I.
/0
IS
41
31
20
6_
pe
03
IS
an
he
7_
54
L_
_2
_2
As
/N
EP
L.
/0
67
t
41
rl
As
02
02
ia
I.
41
et
5_
40
ia
an
0/
0/
IS
36
/V
he
So
EP
12
/V
ds
03
02
EP
L.
04
ie
ut
rl
I_
_2
ie
I.
41
/2
/0
EP
tn
IS
hA
an
02
IS
45
tn
7_
6_
I_
am
L_
me
ds
0/
L.
EP
52
am
IS
Eu
As
41
ri
/H
41
I.
02
L_
/Q
ro
ia
30
IS
45
ca
an
/2
41
ua
pe
/V
L.
62
EP
22
/B
7_
oi
61
/S
ng
ie
41
I.
_2
ra
Eu
EP
40
wi
45
IS
ni
tn
02
zi
I_
ro
_2
45
L.
tz
EP
ng
am
0/
IS
l/
pe
02
41
I.
er
/H
02
EP
L_
Sa
/U
54
0/
IS
la
an
/2
I_
41
oP
ni
75
L.
03
EP
nd
IS
9_
oi
51
41
au
te
/0
I.
/Z
L_
Eu
58
54
IS
lo
dK
2_
EP
41
ur
ro
76
_2
L.
EP
in
/S
Eu
EP
I_
64
ic
pe
02
41
I_
I.
gd
ro
ao
IS
71
64
0/
/S
h
IS
IS
L_
pe
om
Pa
_2
30
03
L.
wi
L_
EP
41
/D
/E
ul
02
41
/0
41
tz
I.
64
en
ng
o
0/
64
1_
29
IS
er
72
ma
la
28
03
L.
72
Eu
la
_2
EP
rk
nd
/0
41
EP
_2
ro
I.
nd
02
/C
64
2_
I_
02
IS
pe
0/
/Z
op
31
Eu
IS
0/
L.
/B
03
ur
EPI
en
L_
ro
41
02
el
/0
ic
EP
ha
.IS
30
41
pe
/2
gi
2_
h
I_
20
ge
64
/B
7_
L.4
um
Eu
EPI
IS
76
n
el
No
EP
/B
ro
160
L_
_2
.IS
rt
gi
I_
pe
ru
41
36
02
hA
um
L.4
IS
/B
ss
64
EPI_
EPI
0/
me
/K
L_
el
67
el
140
03
ri
.IS
es
41
ISL_
_2
gi
s
/0
12
ca
51
se
L.4
02
um
2_
EPI
/M
57
l4155
0/
EPI_
/K
130
Eu
ex
_2
.IS
Lo
03
es
ro
22
02
ic
32_2
ISL_
/0
L.4
se
pe
0/
o/
EPI
2_
l/B
161
03
Me
020/
4144
Eu
.IS
Lo
el
/0
xi
40
ro
EPI_
gi
L.4
1_
03/0
70_2
co
pe
EPI
um
Eu
151
Ci
/B
ISL_
.IS
/H
ro
9_Eu
020/
ty
el
58
ol
pe
L.4
gi
4145
EPI
sb
/B
03/0
EPI
rope
um
164
el
ee
_IS
.IS
/H
80_2
71
6_Eu
/Net
gi
k
L_4
ol
L.4
um
EPI
020/
EPI
sb
164
rope
135
herl
/S
ee
_IS
.IS
in
72
79_
03/0
k
/Net
L_4
ands
L.4
t202
EPI
Ni
5_So
129
165
herl
/Zui
kl
0/0
.IS
72
19_
aa
uthA
L.4
3/0
ands
dHol
s
202
EPI
164
3_E
meri
0/0
.IS
/Zui
land
76
EPI
uro
3/0
L.4
ca/C
_IS
dHol
pe/
EPI
164
2_O
L_4
hile
.IS
Net
67
land
cea
154
EPI
L.4
her
/San
nia
73_
_IS
EPI
151
lan
/Ne
.IS
tiag
L_4
202
57
ds/
EPI
wZe
L.4
154
0/0
EPI
o
Noo
_IS
EPI
155
ala
85_
3/0
_IS
L_4
tdo
.IS
32
nd/
202
9_E
L_4
L.4
155
rp
Auc
0/0
uro
154
144
EPI
35_
kla
3/1
72_
pe/
70
.IS
202
nd
2_E
202
Net
L.4
0/0
uro
145
0/0
EPI
her
3/1
EPI
EPI
80
.IS
pe/
3/1
lan
_IS
_IS
2_E
L.4
1_E
Net
ds
L_4
L_4
uro
135
EPI
uro
her
154
154
pe/
79
.IS
pe/
lan
62_
88_
Net
EPI
L.4
Net
202
ds
202
_IS
her
165
EPI
her
0/0
L_4
0/0
lan
19
.IS
3/0
lan
135
3/1
ds/
L.4
9_E
EPI
66_
ds
3_E
154
Zui
EPI
_IS
uro
202
uro
73
dHo
.IS
L_4
pe/
0/0
pe/
L.4
lla
151
Net
3/0
Net
154
nd
EPI
EPI
55_
2_E
her
85
her
_IS
.IS
202
uro
lan
lan
L.4
L_4
0/0
pe/
ds/
154
ds
151
EPI
3/0
Net
Gel
72
53_
EPI
.IS
1_E
her
der
202
L.4
_IS
uro
lan
lan
0/0
155
L_4
pe/
EPI
ds/
d
35
3/0
164
Bel
.IS
Bla
3_E
69_
EPI
L.4
giu
ric
uro
_IS
202
154
m/H
EPI
um
pe/
L_4
0/0
88
uld
.IS
Bel
151
3/0
enb
L.4
giu
54_
3_E
EPI
154
erg
202
m/H
uro
_IS
EPI
62
0/0
uld
.IS
L_4
pe/
3/0
L.4
164
enb
Bel
EPI
135
1_E
70_
erg
giu
_IS
EPI.
66
uro
202
m/K
L_4
ISL.
pe/
0/0
ess
151
3/0
Bel
4151
56_
el2_E
giu
55
EPI.
202
Lo
EPI_IS
uro
m/K
0/0
ISL.
pe/
raa
3/0
4151
EPI_IS
L_4145
Bel
ine
1_E
53
EPI.
giu
m
uro
L_4156
87_202
ISL.
m/C
pe/
out
4164
Bel
29_202
0/03/0
hui
giu
69
EPI.
EPI_
n
m/H
0/03/0
3_Euro
ISL.
ISL_
uld
4151
4135
4_Euro
enb
pe/Ire
54
erg
EPI_
55_2
EPI.
pe/Uni
ISL.
ISL_
land/L
020/
4164
4145
02/2
tedKin
imeric
70
59_2
7_Eu
EPI.
EPI_
gdom/S
020/
ISL.
rope
ISL_
k
4151
03/0
/Uni
4155
cotlan
56
7_Eu
tedK
25_2
EPI.
rope
d
ISL.
020/
ingd
EPI_
/Net
4145
03/1
om/W
ISL_
87
herl
2_Eu
4155
ales
EPI.
ands
rope
34_2
ISL.
/Zui
/Net
020/
4156
EPI_
29
dHol
herl
03/1
ISL_
EPI.
EPI_
ands
1_Eu
land
4154
ISL.
ISL_
rope
/Noo
60_2
4135
4146
/Net
rdHo
55
020/
29_2
EPI.
herl
llan
03/0
020/
ISL.
ands
EPI_
d
9_Eu
03/0
4145
ISL_
/Zui
rope
59
3_Eu
4146
dHol
/Net
EPI.I
rope
28_2
land
herl
SL.41
/Fra
020/
ands
nce/
5525
03/0
/Fle
Haut
2_Eu
EPI.I
vola
sdeF
rope
SL.41
nd
ranc
/Fra
EPI_ISL_
5534
nce/
e/Co
Haut
mpig
EPI.I
414586_2
EPI_ISL_
sdeF
ne
SL.41
ranc
020/03/0
5460
414523_2
e/Co
EPI.I
mpig
3_Europe
020/02/2
ne
SL.41
EPI_I
/Ireland
4629
SL_41
7_Europe
4526_
EPI.I
/Limeric
/UnitedK
2020/
SL.41
EPI_I
4628
03/03
k
ingdom/E
SL_41
_Euro
EPI.I
5640_
pe/Un
ngland
SL.41
2020/
itedK
4586
03/08
ingdo
_Euro
m/Eng
EPI.I
pe/Un
SL.41
land
itedK
4523
EPI_I
ingdo
SL_41
EPI.IS
m/Sco
5646_
L.4145
tland
EPI_ISL_41
2020/
26
03/03
3593_2020/
_Euro
EPI.IS
EPI_ISL_41
pe/It
L.4156
02/29_Euro
aly
40
6141_2020/
pe/Luxembo
EPI.IS
03/03_Euro
EPI_IS
L.4156
L_4144
urg
46
pe/Denmark
28_202
0/03/0
/Copenhage
EPI.IS
2_Euro
L.4135
pe/Net
n
93
herlan
EPI_IS
ds/Noo
EPI.ISL
L_4164
rdBrab
.416141
79_202
ant
0/03/0
EPI_ISL_4135
5_Asia
EPI.ISL
/Georg
89_2020/03/0
.414428
ia/Tbi
1_Europe/Net
lisi
EPI.ISL
EPI_ISL
herlands/Utr
.416479
_416334
_2020/0
echt
EPI_ISL_406862
2/06_As
EPI.ISL.
ia/Chin
413589
_2020/01/28_Eu
a/Shang
hai
rope/Germany/B
EPI.ISL.
EPI_ISL_
416334
avaria/Munich
408514_2
020/01/0
1_Asia/C
EPI.ISL.4
hina/Hub
06862
EPI_ISL_408515_2
ei/Wuhan
020/01/01_Asia/C
EPI.ISL.4
08514
hina/Hubei/Wuhan
EPI_ISL_4
16024_202
0/03/11_Europe/Uni
EPI.ISL.40
8515
EPI_ISL_41
tedKingdo
5583_2020/
m/Wales
03/03_Nort
EPI.ISL.416
hAmerica/C
024
anada/Brit
ishColumbi
a
EPI_ISL_414
EPI.ISL.4155
487_2020/03
83
/04_Europe/
E P I_ IS L _ 4 1 6 0
Ireland/Cor
3 3 _ 2 0 2 0 /0 3 /0
k
E P I.IS L .4 1 4 4
3 _ S o u th A m e r
87
ica /B ra zil/S a o
P a u lo /S a o P a u
lo
E P I_ IS L _ 4 1 6 4 8
EPI.ISL.416033
8 _ 2 0 2 0 /0 3 /0 3 _ E
u ro p e /P o la n d /Z
ie lo n o g o rskie
E P I.IS L .4 1 6 4 8 8
E P I_ IS L _ 4 1 5 5 3 1 _
2 0 2 0 /0 3 /0 9 _ E u ro p
e /N e th e rla n d s/Z u i
d H o lla n d
E P I.IS L .4 1 5 5 3 1
E P I_ IS L _ 4 1 5 4 9 5 _ 2 0 2
0 /0 3 /1 0 _ E u ro p e /N e th
e rla n d s
E P I.IS L .4 1 5 4 9 5
E P I_ IS L _ 4 1 4 5 0 9 _ 2 0 2 0 /0 2
/2 8 _ E u ro p e /G e rm a n y/N o r
th R h in e W e stp h a lia /H e in sb
e rg D istrict
E P I.IS L .4 1 4 5 0 9
E P I_ IS L _ 4 1 4 5 0 5 _ 2 0 2 0 /0 2 /2 7 _ E u
ro p e /G e rm a n y/N o rth R h in e W e stp h
a lia /H e in sb e rg D istrict
E P I.IS L .4 1 4 5 0 5
E P I_ IS L _ 4 1 4 4 9 7 _ 2 0 2 0 /0 2 /2 5 _ E u ro p e /G e rm a n
y/N o rth R h in e W e stp h a lia /H e in sb e rg D istrict
E P I.IS L .4 1 4 4 9 7

Georgia

ISL_

IS

France

EPI_IS
L_4156
25_202
EPI_IS
0/03/0
L_4164
EPI_
ISL_
9_Nort
52_202
4155
hAmeri
0/03/1
97_2
020/
ca/USA
ISL_
0_Nort
03/1
4146
/Washi
hAmeri
0_No
16_2
rthA
020/
ngton
ca/USA
meri
03/0
EPI_
/Washi
ca/U
8_No
ISL_
SA/W
rthA
ngton
4164
ashi
EPI.
meri
38_2
ISL.
ngto
ca/U
EPI_
020/
4156
n/Se
SA/W
ISL_
03/1
25
attl
ashi
EPI.
4164
0_No
e
ngto
ISL.
34_2
rthA
57_2
4164
n/Ki
020/
meri
020/
52
03/1
rkla
EPI.
ca/U
03/1
EPI_
0_No
nd
ISL.
SA/W
8_No
ISL_
rthA
4155
rthA
ashi
4146
97
meri
meri
ngto
27_2
EPI.
ca/U
ca/U
020/
n
ISL.
SA/W
SA/C
03/0
4146
ashi
EPI_
alif
16
2_Eu
ISL_
ngto
EPI.
orni
rope
4164
ISL.
n
/Fra
a/Sa
EPI_ISL_
4164
91_2
nce/
nDie
38
020/
Haut
goCo
414636_2
EPI.I
03/1
sdeF
unty
5_No
SL.41
ranc
020/03/0
rthA
6434
EPI_ISL_
e/Co
meri
mpig
EPI.I
4_Europe
ca/U
414635_2
ne
SL.41
SA/W
/France/
6457
I/Da
020/03/0
neco
EPI.I
Haut
unty
4_Europe
SL.41
sdeFranc
4627
/France/
EPI_I
e/Compig
EPI.I
EPI_I
SL_41
HautsdeF
SL.41
ne
SL_41
5543_
6491
rance/Co
6495_
2020/
2020/
03/13
EPI.I
mpigne
03/10
_Nort
SL.41
_Euro
4636
hAmer
EPI_I
pe/Fr
ica/U
SL_41
ance/
EPI.I
SA/Ut
6510_
SL.41
Hauts
ah
2020/
4635
deFra
EPI_I
03/06
nce/C
SL_41
_Euro
EPI.IS
ompig
4625_
pe/Fr
L.4155
2020/
ne
ance/
43
02/26
Breta
EPI_ISL_41
_Euro
EPI.IS
gne/R
pe/Fr
L.4164
ennes
6498_2020/
ance/
95
Paysd
EPI_IS
03/11_
elaLo
EPI.IS
L_4146
Europe/Fra
ire/N
L.4165
30_202
antes
10
nce/IledeF
0/03/0
3_Euro
EPI.IS
rance/Garc
pe/Fra
L.4146
EPI_IS
nce/Ha
25
hes
L_4165
utsdeF
05_202
rance/
EPI.ISL
0/03/0
EPI_ISL_4146
Compig
.416498
2_Euro
ne
pe/Fra
34_2020/03/0
nce/Br
EPI.ISL
etagne
4_Europe/Fra
.414630
/Renne
nce/HautsdeF
s
EPI.ISL
rance/Compig
EPI_ISL
.416505
_415650
ne
_2020/0
3/02_Eu
EPI.ISL.
rope/Fr
414634
EPI_ISL_414642
ance/ID
F
_2020/03/08_Eu
EPI_ISL_
EPI.ISL.
416502_2
415650
rope/Finland
020/02/2
6_Europe
/France/
EPI.ISL.4
Bretagne
14642
EPI_ISL_415481_2
/Rennes
020/03/08_Europe
EPI.ISL.4
16502
/Netherlands
EPI_ISL_4
15487_202
EPI.ISL.41
0/03/13_E
5481
urope/Net
EPI_ISL_41
herlands
6511_2020/
03/07_Euro
EPI.ISL.415
pe/France/
487
EPI_ISL_416
Bretagne/R
496_2020/03
ennes
/10_Europe/
EPI.ISL.4165
France/Haut
11
sdeFrance/C
ompigne
EPI_ISL_4165
06_2020/03/0
EPI.ISL.41649
3_Europe/Fra
6
nce/Bretagne
/Rennes
EPI_ISL_416513_2020/03/07_
EPI.ISL.416506
Europe/France/Bretagne/Ren
nes
EPI.ISL.416513
EPI_ISL_416509_2020/03/06_Euro
pe/France/Bretagne/Rennes
EPI.ISL.416509
EPI_ISL_416512_2020/03/07_Europe/Fra
nce/Bretagne/Rennes
EPI.ISL.416512
EPI_ISL_415159_2020/02/29_Europe/Belgium/Leu
ven
EPI.ISL.415159
EPI_ISL_415649_2020/03/05_Europe/France/Hauts-de-France/
Crpy-en-Valois
EPI_

EPI_

EP
I_

Finland

ng
do
ng
i
ua
ha
/G
ng
ty
na
ha
un
hi
/S
Co
/C
n
na
no
ia
ua
hi
la
As
oy
/C
So
ty
1_
Ta
ia
a/
ai
un
/0
n/
As
ni
gh
Co
g
02
wa
1_
n
or
an
no
an
0/
ai
ha
/0
if
Sh
la
ji
/T
02
Wu
02
al
a/
So
he
no
ia
i/
/C
0/
in
a/
/Z
la
As
be
SA
02
ni
Ch
na
So
5_
/U
Hu
_2
or
2_
hi
a/
/2
ca
a/
67
if
/0
/C
ni
ey
01
ri
in
al
63
02
ia
or
dn
0/
me
Ch
IS
/C
41
0/
As
if
Sy
02
hA
6_
SA
I_
L_
7_
02
s/
al
on
_2
rt
/2
/U
EP
IS
le
ne
/1
/C
_2
yt
15
No
ca
12
Wa
I_
ur
01
es
15
la
19
7_
ri
9/
th
bo
u
EP
at
0/
12
/C
41
/2
me
01
ou
el
ho
St
02
12
ia
L_
02
hA
_2
wS
/M
gz
ed
_2
or
MT
61
IS
0/
rt
ia
Ne
32
an
it
28
ct
38
02
No
I_
or
a/
73
/H
Un
41
42
Vi
7_
_2
67
EP
ct
li
na
00
L.
3_
a/
40
63
/2
Vi
59
ra
hi
IS
A0
/2
li
L_
41
a/
02
st
35
I.
/C
CN
02
ra
L.
IS
li
0/
Au
EP
41
ia
IS
0/
st
I_
ra
a/
02
L_
As
I.
Au
02
15
EP
st
15
ni
_2
IS
8_
EP
19
5_
_2
12
Au
ea
58
I_
/2
41
/2
re
12
35
a/
Oc
35
L.
01
EP
MT
po
01
88
ni
5_
IS
41
0/
ga
0/
32
11
ea
/2
I.
L_
02
28
re
in
73
02
MT
Oc
EP
01
IS
42
_2
00
po
/S
_2
5_
0/
40
I_
74
A0
ga
ia
44
/2
59
L.
02
CN
EP
64
in
re
As
35
01
75
IS
_2
41
/S
po
6_
41
I.
0/
00
77
ia
L.
L_
ga
a
/0
EP
02
MT
89
IS
As
in
re
IS
02
_2
40
I.
/S
4_
Ko
I_
0/
11
58
35
EP
L_
ty
ia
th
/0
a
02
EP
35
64
88
un
IS
As
ou
02
re
_2
41
11
ng
41
Co
I_
/S
4_
0/
L.
Ko
MT
36
do
L_
ge
EP
IS
ia
/0
02
th
05
ng
IS
an
I.
As
02
ou
_2
41
ua
Or
I_
44
EP
74
6_
0/
/S
15
/G
L_
a/
75
64
EP
/0
02
ia
07
na
IS
00
41
ni
02
As
_2
41
hi
MT
L.
I_
or
77
0/
6_
16
/C
L_
IS
89
if
EP
02
/0
07
I.
ia
40
IS
al
EP
_2
02
L.
41
As
11
I_
/C
IS
17
0/
64
L_
1_
EP
es
s
I.
41
02
30
/0
IS
at
ri
EP
L.
36
_2
41
02
I_
St
Pa
IS
05
re
18
L_
0/
e/
EP
ed
I.
41
s
po
30
IS
02
nc
it
EP
L.
15
ri
ga
41
ra
_2
I_
Un
IS
07
Pa
in
-F
L_
63
EP
2_
I.
re
en
41
e/
/S
de
IS
EP
38
/2
po
L.
ed
s
nc
16
ia
eI_
41
IS
01
ga
ri
Sw
ra
07
As
Il
I.
L_
EP
in
0/
Pa
41
7_
-F
7_
e/
EP
IS
/S
L.
02
e/
de
/0
17
nc
/2
IS
ia
nc
I_
_2
e02
is
ra
01
130
I.
ra
As
EP
Il
68
0/
ar
/F
0/
EP
-F
3_
L.4
e/
44
02
/P
pe
18
02
de
/0
nc
99
ce
_2
.IS
ro
_2
130
e02
ra
an
MN
71
Eu
13
EPI
Il
0/
/F
L.4
Fr
aris
35
3_
63
07
e/
02
pe
e.IS
/2
09
41
nc
138
ro
_2
ce/P
-d
01
MT
ra
L_
EPI
Eu
14
le
L.4
0/
/F
IS
3_
Fran
/I
07
02
.IS
pe
I_
/2
ce
41
_2
ro
EPI
EP
-dean
01
L_
68
97
Eu
Fr
0/
IS
65
3_
944
/Ile
e/
02
I_
40
/2
op
_2
MN9
i
EP
L_
01
71
ance
ur
96
ha
13
0/
IS
Fr
_E
935
65
ng
02
I_
107
28
40
MT0
_2
ope/
EP
ng
1/
L.4
/Sha
L_
20
14
/0
IS
.IS
_Eur
07
hsiu
20
hina
107
I_
EPI
41
20
EP
L.4
/Kao
1/28
L_
9_
ia/C
97
an
/0
.IS
IS
21
As
065
iw
I_
2_
EPI
411
2020
L.4
EP
L_
96
ia/Ta
02/0
ong
.IS
IS
220_
065
EPI
I_
ngK
3_As
020/
411
L.4
EP
/Ho
20
.IS
01/2
25_2
ong
ISL_
sia
107
0/
EPI
63
I_
ngK
02
0_A
L.4
41
EP
19
/Ho
.IS
1/3
31_2
ISL_
112
ong
EPI
sia
0/0
L.4
ngK
4060
5_A
EPI_
202
20
.IS
/Ho
2/2
29_
ISL_
112
EPI
ong
sia
0/0
L.4
120
EPI_
ngK
9_A
202
25
.IS
L_4
/Ho
2/0
163
EPI
17_
_IS
sia
ong
L.4
0/0
145
EPI
.IS
31
2_A
ngK
202
L_4
EPI
060
2/1
/Ho
27_
_IS
L.4
sia
0/0
145
EPI
.IS
29
s
0_A
202
L_4
e
EPI
120
nne
2/1
69_
_IS
Rom
L.4
/Re
0/0
145
ly/
.IS
EPI
17
gne
202
y
s
L_4
EPI
Ita
145
eta
28_
nne
tal
_IS
L.4
pe/
/Br
/Re
.IS
0_I
145
uro
EPI
27
nce
gne
EPI
1/3
L_4
145
9_E
Fra
eta
L.4
0/0
_IS
1/2
pe/
/Br
.IS
202
EPI
0/0
69
uro
EPI
nce
145
56_
202
5_E
Fra
L.4
661
74_
e
3/0
pe/
.IS
28
Rom
MT0
129
0/0
EPI
uro
145
ly/
L_4
202
1_E
L.4
Ita
_IS
07_
3/0
hou
.IS
pe/
EPI
165
EPI
ngz
0/0
uro
L_4
/Ha
202
56
1_E
i
_IS
ina
03_
661
1/3
lis
74
EPI
/Ch
MT0
165
0/0
129
Tbi
sia
L_4
L.4
202
ia/
5_A
_IS
.IS
i
46_
org
07
1/2
EPI
EPI
lis
105
/Ge
165
0/0
Tbi
sia
L_4
L.4
202
ia/
.IS
0_A
_IS
09_
i
03
org
EPI
3/1
EPI
157
165
lis
/Ge
0/0
L.4
L_4
Tbi
sia
202
.IS
_IS
ia/
1_A
43_
46
EPI
org
EPI
3/1
156
4105
/Ge
n
0/0
L_4
ISL.
sia
gto
202
_IS
hin
7_A
EPI.
09
ngland
80_
EPI
Was
2/2
4157
164
es/
0/0
gdom/E
L_4
ISL.
tat
202
_IS
EPI.
43
edS
tedKin
41_
i
EPI
4156
nit
156
7_U
ISL.
pe/Uni
L_4
elsink
2/2
_IS
EPI.
80
nd
0/0
5_Euro
EPI
land/H
4164
ngla
202
ISL.
0/02/2
om/E
16_
pe/Fin
EPI.
637
41
ingd
nd
09_202
MT1
3_Euro
4156
tedK
ngla
ISL.
/Uni
L_4140
0/03/0
om/E
EPI.
_IS
202
rope
ingd
EPI
03_
nd
9_Eu
tedK
3716
ngla
02/0
L_4136
/Uni
MT16
om/E
09
020/
rope
4140
ingd
EPI_IS
16_2
8_Eu
nd
ISL.
tedK
4121
02/2
ngla
EPI.
/Uni
ISL_
03
020/
om/E
rope
4136
EPI_
07_2
ingd
5_Eu
ISL.
4140
tedK
EPI.
02/2
16
/Uni
ISL_
020/
4121
rope
EPI_
05_2
ISL.
ands
8_Eu
4140
EPI.
herl
and
02/2
a
07
ISL_
cotl
/Net
020/
Velh
4140
EPI_
om/S
rope
Vila
06_2
ISL.
ingd
8_Eu
nto/
EPI.
4140
tedK
03/0
05
toSa
ISL_
ia
/Uni
4140
020/
piri
EPI_
ISL.
rope
l/Es
78_2
l/Brasil
EPI.
9_Eu
razi
4154
03/0
ca/B
4006
ISL_
toFedera
020/
meri
EPI_
SL.41
uthA
30_2
l/Distri
EPI.I
9_So
4156
aoPaulo
5478
02/2
ISL_
ca/Brazi
020/
SL.41
EPI_
oPaulo/S
28_2
EPI.I
uthAmeri
l/Sa
4151
4_So
razi
5630
ISL_
nt
SL.41
EPI_
020/03/0
merica/B
Braba
EPI.I
Noord
416032_2
8_SouthA
5128
ands/
SL.41
EPI_ISL_
therl
020/02/2
EPI.I
land
16_2
pe/Ne
4130
m/Eng
_Euro
6032
ingdo
SL.41
03/06
EPI_ISL_
itedK
EPI.I
2020/
pe/Un
4451_
3016
_Euro
SL_41
SL.41
02/26
EPI_I
EPI.I
2020/
4011_
51
h
l
SL_41
L.4144
Zuric
Brazi
EPI_I
EPI.IS
land/
2/28_
itzer
11
020/0
pe/Sw
Brabant
L.4140
808_2
_Euro
EPI.IS
MT126
02/26
ands/Noord
2020/
3019_
pe/Netherl
08
SL_41
MT1268
EPI_I
03/09_Euro
ds
herlan
19
5512_2020/
L.4130
pe/Net
d
EPI.IS
0_Euro
cotlan
EPI_ISL_41
0/03/1
gdom/S
92_202
tedKin
.415512
pe/Uni
L_4154
EPI.ISL
0_Euro
EPI_IS
dHolland
0/03/1
31_202
.415492
herlands/Zui
L_4156
EPI.ISL
EPI_IS
6_Europe/Net
ds
.415631
68_2020/03/0
therlan
EPI.ISL
rope/Ne
EPI_ISL_4144
3/07_Eu
414468
_2020/0
ds
EPI.ISL.
_415491
EPI_ISL
rope/Netherlan
415491
echt
_2020/03/13_Eu
EPI.ISL.
ands/Utr
/Netherl
EPI_ISL_415486
2_Europe
15486
020/03/1
EPI.ISL.4
415527_2
EPI_ISL_
i/Wuhan
15527
01/01_China/Hube
EPI.ISL.4
/Shenzhen
CNA0007334_2020/
/Guandong
sia/China
0/01/15_A
CNA0007334
zhen
03934_202
ndong/Shen
EPI_ISL_4
934
/China/Gua
EPI.ISL.403
01/16_Asia
6595_2020/
EPI_ISL_40
95
uhan
EPI.ISL.4065
ina/Hubei/W
19/12/30_Ch
MN996527_20
/Hubei/Wuhan
MN996527
0_Asia/China
98_2019/12/3
EPI_ISL_4128
EPI.ISL.412898
_China/Hubei/Wuhan
NMDC60013002-06_2019/12/30
_2

61

38

41

L_

8

NMDC60013002-08_

EPI_ISL_
408479_2

EPI_ISL_411927

NMDC600

13002-1

LC521925_202

A23403G

T28144C

5

6

7

8

9

99

99
99

98

4

Block 1 (27 kb)
1
2
3
97

98
99

C18060T

9

A17858G

T28144C

8

C17747T

A23403G

7

C14408T

C18060T

6

C8782T

A17858G

5

C3037T

C17747T

4

Block 1 (27 kb)
1
2
3

C241T

C14408T

C8782T

B

C3037T

C241T

A

98
97

98

97

97

99
98
98

99

99

99
98

99

98

98
99

99

99
98

99
97

99

99

98
98

98

99

1
2
3
4
5
6
7
8
9

1
2
3
4
5
6
7
8
9

1
2
3
4
5
6
7
8
9

1
2
3
4
5
6
7
8
9

99

C C C C C A C A T

.423

.423

T T C T C A C G T .454

.454

T T C T C A C G T

.288

.288

C C C C C A C A T .324

.324

C C T C C A C A C .148

.148

C C T C T G T A C .123

.123

.122

.122

C C T C C A C A C .063

.063

C C T C T G T A C

0.25

0.00

18060T

TTCTCACGT(H1)
17747T

23403G

CCCCCACAT(H2)

17858G

0.75

0.50

0.25

0.00

28144C

0.75

0.50

CCCA
TTTG
CAC

CCTCTGTAC(H3)

SouthKorea
China
Japan
USA
Canada
Australia
Spain
UK
Germany
Netherland
Austria
Portugal
Belgium
Italy
France
Switzerland
Brazil

SouthKorea
China
Japan
USA
Canada
Australia
Spain
UK
Germany
Netherland
Austria
Portugal
Belgium
Italy
France
Switzerland
Brazil

14408T

3037T

SouthKorea
China
Japan
USA
Canada
Australia
Spain
UK
Germany
Netherland
Austria
Portugal
Belgium
Italy
France
Switzerland
Brazil

B
SouthKorea
China
Japan
USA
Canada
Australia
Spain
UK
Germany
Netherland
Austria
Portugal
Belgium
Italy
France
Switzerland
Brazil

1.00

241T

SouthKorea
China
Japan
USA
Canada
Australia
Spain
UK
Germany
Netherland
Austria
Portugal
Belgium
Italy
France
Switzerland
Brazil

1.00

SouthKorea
China
Japan
USA
Canada
Australia
Spain
UK
Germany
Netherland
Austria
Portugal
Belgium
Italy
France
Switzerland
Brazil

Frequency of each specific site
1.00

SouthKorea
China
Japan
USA
Canada
Australia
Spain
UK
Germany
Netherland
Austria
Portugal
Belgium
Italy
France
Switzerland
Brazil

Frequency of major haplotypes of the 4,3 and 9 specific sites

A
8782T

0.75

0.50

country
SouthKorea
China
Japan
USA
Canada
Australia
Spain
UK
Germany
Netherland
Austria
Portugal
Belgium
Italy
France
Switzerland
Brazil

Asia

NorthAmerica
Ocieania

Europe

SouthAmerica

0.25

0.00

1.00
TGT

0.75

country

0.50

0.25

0.00

1.00
CCTCCACAC(H4)

0.75

0.50

0.25

0.00
SouthKorea
China
Japan
USA
Canada
Australia
Spain
UK
Germany
Netherland
Austria
Portugal
Belgium
Italy
France
Switzerland
Brazil

Asia

NorthAmerica
Ocieania

Europe

SouthAmerica

B

COL

the 9 specific sites

other mutation sites

0.5

H1

0.4
0.3
0.2
0.1
0.0
0

10000

20000

30000

0

10000

20000

30000

0

10000

20000

30000

0

10000

20000

30000

0.5

H2

0.4
0.3
0.2
0.1
0.0

0.5

H3

0.4
0.3
0.2
0.1
0.0

0.5
0.4

H4

A

0.3
0.2
0.1
0.0

Pos

Australia
Brazil
Canada
USA
China
Japan
South_Korea

H1

Austria
Belgium
France
Germany
Italy
Netherlands
Portugal
Spain
Switzerland
United_Kingdom

H5
H2

H4

H3

241T
0.16

3037T

8782C

●

R = 0.46 , p = 0.06451

●

R = 0.47 , p = 0.055

●

●

14408T

●

●
●

●

R = 0.32 , p = 0.2105

●

●
●
●

●
●

●

R = 0.44 , p = 0.08004

●

●

●

●
●

0.12
●

0.08

●

●

0.04

●

●
●

●

●

●

● ●

●

●
●●●

● ●

●
●
●

●

●

23403G

●

R = 0.18 , p = 0.4962

●
●
●

● ●

●

18060C

●

●

●

●

17858A

●

●

●

●

17747C

Estimated death rate

●

●

R = 0.18 , p = 0.4799

●

●
●

●

●
●

0.16

●
●

●

●

●

●

●

●

●

●

●

R = 0.18 , p = 0.4807

●
●
●

●

●

●

●

●

●

●

R = 0.46 , p = 0.06523

●

●

●
●

0.12

0.08

●

●

●
●
●

●

●
●
●

0.04

●

●

●

R = 0.33 , p = 0.1906

●
●
●
●

● ●

●

TTCTCACGT(H1)
●

R = 0.18 , p = 0.4802

●

●

●

●

CAC
●

R = 0.45 , p = 0.06913

●

●

●

TTTG
●

●

●

●

●
●
●

●

28144T

●

●
●
●

●

●
●
●

●

0.16

●

●
●
●

●

●

●
●
●

●
●

●

R = 0.45 , p = 0.07226

●

●

●

●
●

0.12
●

●

0.08

●
●

●

●
●
●
●
●●●

●

0.25

●
●

●

●
●
●

●

0.50

0.75

● ●

●
●

1.000.00

0.25

0.50

●

●

1.000.00

0.25

0.50

0.75

●
●

●

● ●

●

●

0.75

●

●

●

●
●
●

●
●

0.00

●

●

●

●

0.04

●

●

1.000.00

Frequency of 9 specific sites and haplotypes

0.25

0.50

0.75

1.00

10

-3

s.e. (Ka)
10

-3

Ks (mean)
10

-3

s.e. (Ks)
10

-3

Ka/Ks

s.e.

(mean)

(Ka/Ks)

Hypothesis

P-value*

P-value*

622 genomes

3624 genomes

SARS-CoV

0.985

0.018

1.310

0.049

0.760

0.038

Ka/Ks ( SARS-CoV < SARS-CoV-2)

0.139

0.084

MERS-CoV

1.319

0.040

4.887

0.096

0.260

0.003

Ka/Ks ( MERS-CoV < SARS-CoV-2)

0.000

0.000

622 genomes

0.231

0.004

0.265

0.005

1.008

0.020

3624 genomes

0.287

0.002

0.298

0.002

1.094

0.010

SARS-CoV-2
Note: *One-sided Mann-Whitney U-test for the means of two independent samples.

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Ka (mean)

MERS-CoV
SARS-CoV-2

95% CI (10-3)
0.489, 1.654
0.800, 2.380
1.392, 1.632
0.876, 1.370
1.418, 1.796

tMRCA
2002/6/28
spring of 2002
2012/6/7
2012/3
2019/9/27

95% CI
2002/1/19, 2002/11/3
2012/6/4, 2012/6/9
2011/12, 2012/6
2019/8/28, 2019/10/26

references
this study
17

this study
18

this study

17. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, et al. Moderate mutation rate in the SARS coronavirus genome and its
implications. BMC Evol Biol. 2004;4:21.
18. Cotten M, Watson SJ, Zumla AI, Makhdoom HQ, Palser AL, Ong SH, et al. Spread, circulation, and evolution of the
Middle East respiratory syndrome coronavirus. mBio. 2014;5(1).

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

SARS-CoV

substitution rate (10-3)
1.050
1.516
1.120
1.601

Ref

Alt

pi

Cluster 1

Cluster 2

Cluster 3

Major

Major

Major

allele

frequency

pi

allele

frequency

pi

allele

frequency

Fst

Gene

Mutation

Protein

codon

region

type

changed

changed

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Pos

Impact

241

C

T

0.0000

C

1.0000

0.0109

C

0.9945

0.0000

T

1.0000

0.9912

5'UTR

upstream

NA

NA

MODIFIER

3037

C

T

0.0000

C

1.0000

0.0109

C

0.9945

0.0000

T

1.0000

0.9912

gene-orf1ab

synonymous

924F

2772ttC>ttT

LOW

8782

C

T

0.0000

T

1.0000

0.3863

C

0.7390

0.0000

C

1.0000

0.5821

gene-orf1ab

synonymous

2839S

8517agC>agT

LOW

14408

C

T

0.0000

C

1.0000

0.0055

C

0.9973

0.0000

T

1.0000

0.9956

gene-orf1ab

missense

4715P>L

14144cCt>cTt

MODERATE

17747

C

T

0.0735

T

0.9620

0.0000

C

1.0000

0.0000

C

1.0000

0.9752

gene-orf1ab

missense

5828P>L

17483cCt>cTt

MODERATE

17858

A

G

0.0497

G

0.9747

0.0000

A

1.0000

0.0000

A

1.0000

0.9836

gene-orf1ab

missense

5865Y>C

17594tAt>tGt

MODERATE

18060

C

T

0.0000

T

1.0000

0.0164

C

0.9918

0.0000

C

1.0000

0.9761

gene-orf1ab

synonymous

5932L

17796ctC>ctT

LOW

23403

A

G

0.0000

A

1.0000

0.0164

A

0.9918

0.0000

G

1.0000

0.9869

gene-S

missense

614D>G

1841gAt>gGt

MODERATE

28144

T

C

0.0000

C

1.0000

0.3915

T

0.7335

0.0000

T

1.0000

0.5785

gene-ORF8

missense

84L>S

251tTa>tCa

MODERATE

s.e. (Ka)10-3

Ks (mean) 10-3

s.e. (Ks)10-3

Ka/Ks (mean)

s.e. (Ka/Ks)

Hypothesis

P-value*

H1

0.510

0.057

0.498

0.056

1.099

0.010

Ka/Ks ( H3 < H1)

0.000

H2

0.347

0.042

0.334

0.044

1.268

0.023

Ka/Ks ( H3 < H2)

0.000

H3

0.298

0.007

0.397

0.009

0.795

0.010

-

-

H4

0.334

0.023

0.414

0.019

0.796

0.019

-

-

H1

0.416

0.011

0.384

0.011

1.178

0.005

Ka/Ks ( H3 < H1)

0.000

H2

0.332

0.014

0.316

0.014

1.224

0.012

Ka/Ks ( H3 < H2)

0.000

H3

0.305

0.004

0.401

0.005

0.809

0.007

-

-

H4

0.354

0.010

0.477

0.009

0.749

0.010

-

-

3624 genomes

16373 genomes

Note: *One-sided Mann-Whitney U-test for the means of two independent samples.

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.24.058933; this version posted June 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Ka (mean) 10-3

